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Preface 
In the pathogenesis of chronic complications of diabetes - both micro- and macro-
vascular complications -, low-grade systemic inflammation is a major contributor in 
the development of cell and tissue damage induced by the metabolic abnormalities 
that characterize the disease. 
On the other hand, large portions of the human genome are dedicated to 2 
functions closely related to each other: the innate immunity and the energy 
metabolism of the cell. From the evolutionary point of view, for most of the human 
history, the pressure from infection, trauma and starvation have selected individuals 
with more pronounced inflammatory response and gluconeogenesis capacity and, 
therefore, insulin resistance. However, in more recent times, due to the absence of 
these threats, or even for the transition to a state of oversupply, these features have 
produced a maladaptive response that is at the basis of the tumultuous development 
of metabolic and vascular diseases just mediated by the interactions between these 
two biological functions. 
 
1.1 The metabolic syndrome  
 
The metabolic syndrome (MS) is defined by a cluster of interrelated factors, such 
as dyslipidemia, elevation of arterial blood pressure (BP) and dysregulated glucose 
homeostasis (Kassi et al. 2011), that confer an increased risk for cardiovascular 
disease, chronic kidney disease (CKD) (Kurella et al. 2005) and non-alcoholic 
steatohepatitis (NASH) (Marchesini et al. 2003). Among the disorders clustering in 
the MS, dyslipidemia, that is elevated triglycerides and apolipoprotein B (apoB)-
conteining lipoproteins, and low high-density lipoproteins (HDL), has been 
recognized as a powerful independent risk factor for cardiovascular disease (Castelli 
et al. 1986) and NASH. In the liver, insulin resistance and the MS cause fat 
accumulation via increased fatty acids (FA) delivery from adipose tissue and 
enhanced hepatic FA import and synthesis exceeding the rate of FA export and 
catabolism. In contrast, a causal role for dyslipidemia and MS in renal disease has 
been demonstrated only in studies in experimental animal models, showing that a 
high saturated fat and/or cholesterol intake induces glomerulosclerosis and tubulo-
interstitial damage, associated with renal lipid accumulation, altered cellular lipid 
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metabolism and non-enzymatic lipid modifications causing lipotoxicity (Jiang et al. 
2005; Kume et al. 2007; Deji et al. 2009; Iacobini et al. 2009). In addition, the 
increased lipid synthesis and deposition driven by the up-regulation of sterol 
regulatory element-binding protein-1 was shown to contribute significantly to renal 
injury occurring in experimental diabetes (Sun et al. 2002).  
The MS is characterized by a low-grade chronic inflammation, often referred to as 
“metaflammation”, being a metabolically triggered inflammation. In this condition, 
nutrients and metabolic surplus, rather than pathogens, act as principal triggers of the 
inflammatory response engaging the same molecules and signaling pathways as 
those involved in classical inflammation (Hotamisligil et al. 2006). However, 
although inflammation and consequent fibrosis were proposed as possible 
pathogenetic mechanisms linking lipotoxicity to renal and liver damage (Deji et al. 
2009; Iacobini et al. 2009), to date, the molecular basis of activation of renal and 
liver pro-inflammatory and fibrogenic signaling pathways by an obesogenic high-fat 
diet (HFD) is still poorly defined. 
 
1.2 Innate immunity  
 
The inflammatory response mediated by the innate immune system plays an 
important role in host safeguard and it is one of the first lines of defense to be 
activated by pathogens. In the case of microbial invasion, it often plays a critical role 
in clearing, containing, and/or slowing the infection.  
Innate immunity is characterized by its ability to recognize a wide range of 
pathogens such as viruses, bacteria, fungi and parasites by a limited number of 
germline-encoded receptors called pattern-recognition receptors (PRRs). PRRs are 
able to recognize several well-conserved microbial structures, which are known as 
pathogen-associated molecular patterns (PAMPs), triggering proinflammatory 
signaling. Examples of PAMPs are sugars, flagellin, and the cell wall components 
peptidoglycan (PGN) and lipopolysaccharide (LPS). It is now clear, however, that 
the innate immune system can also respond to non-microbial stimuli. Interestingly, 
accumulating evidence reveals that some of PRRs are also able to sense various 
endogenous signals that arise during tissue or cell damage, termed damage-
associated molecular patterns (DAMPs), as well as particulate exogenous non-
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microbial compounds, like asbestos fibers or silica. During infection, DAMPs 
provides additive signals to those induced by PAMPs. However, DAMP signaling 
can also trigger inappropriate inflammation in sterile types of injury and thereby 
contribute to unnecessary organ damage and dysfunction (Anders and Muruve 2011). 
Both infectious and sterile stimuli ultimately lead to the same downstream vascular 
and cellular manifestations of inflammation (Figure 1). 
PRRs can be found both in immune cells, like macrophages, monocytes, dendritic 
cells (DCs), neutrophils, and non-immune cells, i.e. epithelial cells. At least five 
distinct genetic and functional clades of PRRs are known: Toll-like receptors 
(TLRs), the receptor for advanced glyco- and lipoxidation end-products (RAGE), C-
type lectin receptors (CLRs), retinoic acid–inducible gene (RIG)-I-like receptors 
(RLRs), and the nucleotide-binding domain, leucine-rich repeat–containing (NBD-
LRR) proteins (NLRs). Some of the TLRs as well as the C- type lectin receptors are 
found on the cell surface; additionally, the endosomal compartment contains some 
TLRs that sense nucleic acids. Unlike TLRs and CLRs, RLRs and NLRs are 
cytosolic proteins that survey for the presence of intracellular microbial molecules or 
danger signals.  
Most of the PRRs triggers nuclear factor (NF) -kB, IFN regulatory factors, and 
mitogen-activated protein kinase signaling pathways resulting in the transcription of 
proinflammatory chemokines and cytokines or proteins involved in antigen 
presentation and processing. In the last years, however, a prominent subgroup of 
NLRs involved in the post-translational activation of pro-inflammatory cytokines 
such as interleukin (IL)-1β and IL18 has been identified. The generation of mature 
IL-1β and IL-18, indeed, involves two separate processes to avoid their inappropriate 
and deleterious release: the induction of NF-kB-dependent mRNA expression and 
translation of the procytokine upon activation by most PRRs (signal 1) followed by 
cleavage of the procytokine and release of its mature and active form (signal 2). The 
latter event depends on the assembly and activation, in response to an appropriate 
microbial and non-microbial stimulus, of multiprotein complexes termed 
‘inflammasomes’ that mediate caspase-1-dependent processing of the procytokines 
(Anders et al. 2001; Bauernfeind et al. 2011) (Figure 1). 
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Figure 1. How pattern recognition receptors induce innate immunity. Several groups of 
extracellular or intracellular innate pattern recognition receptors exist. TLR-1/2/4/5/6 recognize 
microbes at the cell surface. TLR3/7/8/9 recognize viral and bacterial nucleic acids in intracellular 
endosomes. All TLRs use the intracellular adaptor myeloid differentiation primary response gene (88) 
(MyD88) for downstream signaling, except for TLR3, which uses TIR-domain-containing adapter-
inducing interferon-β (TRIF). TLR4 uses MyD88 and TRIF. All TLRs can induce the expression of 
NF-kB-dependent genes, including most proinflammatory cytokines and chemokines. TLRs also 
induce the procytokines IL-1β and IL-18 (signal 1). These cytokines need caspase-1 activation as a 
second step before they can be released. Caspase-1 activation is under the control of the 
inflammasomes. For example, potassium efflux, lysosomal cathepsin leakage in the cytosol, or 
oxidative stress can trigger the NLRP3 inflammasome that includes the adaptor ASC and caspase 1. 
All cytokine classes amplify innate immunity by interacting with their respective cytokine receptors, 
as shown at the bottom of the figure. All inflammasome-related cytokines ligate their receptors to 
trigger MyD88-dependent signaling. (Anders and Muruve 2011) 
 
 
 
 
 
 
	   10	  
1.3 Inflammasomes 
 
Some NLRs have recently been identified as component of the inflammasome 
complex, a multiprotein oligomer whose assembly leads to caspase-1 activation. 
Specifically, the inflammasome’s NLR component is able to sense the pro-
inflammatory stimuli, inducing in turn the platform assembly.  
NLRs display a tripartite structural organization consisting of (Bauernfeind et al. 
2011) 
• C-terminal leucine-rich repeats (LRRs), suited for ligand binding, 
although a clear receptor-ligand interaction has not been demonstrated for 
any NLR yet; 
• a central NBD or NACHT domain (nucleotide-binding domains or NAIP, 
CIITA, HET-E, and TP-1) that is thought to oligomerize upon activation 
in the presence of ATP;  
• an N-terminal effector domain necessary for signal transduction through 
protein–protein interactions. Based on the molecular structure of the N-
terminal domain (Ting et al. 2008), different NLR subfamilies can be 
distinguished. For the purpose of the work we refer only to the two major 
subfamilies: the NLRCs, to which also belong NODs (NOD-like receptor 
family), containing a caspase recruitment domain (CARD) and the 
NLRPs, which instead contain a pyrin domain (PYD). CARD and PYD 
domains are able to interact only with subunits of identical chemical 
nature, CARD with CARD and PYD with PYD. (Figure 2). 
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Figure 2. Human inflammasome-related genes. The NLRP subfamily of NLR genes consists of 14 
members that are typified by an N-terminal PYD in addition to conserved NACHT and leucine-rich 
repeat domains common to all NLR genes. NLRP1 is unique in that it also carries a C-terminal 
CARD. NLRC4 (Ipaf1) is a member of the NLR family with an N-terminal CARD that can directly 
interact with caspase-1. AIM2 is a DNA interacting human interferon-inducible 200 protein with an 
N-terminal PYD that can form a caspase1-activating inflammasome but does not belong to the NLR 
family. Inflammasomes also generally consist of the adaptor protein ASC and the cystine protease 
caspase-1 (Anders and Muruve 2011). 
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Exposure to a specific DAMP or PAMP leads to the oligomerization of some 
NLRs via their NACHT domain and the consequent recruitment of the adapter 
protein ASC (apoptosis-associated speck-like protein containing a CARD) via direct 
interaction PYD-PYD. ASC, in turn, recruits procaspase1 via a homotypic CARD 
interaction to complete the formation of inflammasome. Recruitment to the 
inflammasome triggers procaspase-1 autoprocessing and generation of the active 
forms 10 kDa (p10) and 20 kDa (p20) that associate into enzymatically active p10/20 
heterodimers. In turn, active caspase-1 cleaves the 31 kDa pro-IL-1β and the 22 kDa 
pro-IL-18 into their active and secreted forms (17 kDa and 18 kDa respectively) 
(Anders et al. 2011) (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Simplified model of NLRP3 structure and activation. (1) Exposure to a DAMP or PAMP 
releases NLRP3, which oligomerizes via its NACHT domain. (2) NLRP3 oligomerization recruits the 
adapter protein ASC to the complex. ASC then recruits caspase-1 via a homotypic CARD interaction 
to complete the formation of the inflammasome.(3) Recruitment to the inflammasome triggers 
caspase-1 autoprocessing and generation of the active p10/20 heterodimeric enzyme. (4) Active 
caspase-1 cleaves pro-IL-1β and pro-IL-18 into their active and secreted forms (Anders and Muruve 
2001). 
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Caspase 1 is the best described inflammatory caspase, so termed because the 
precursor forms of the inflammatory cytokines IL-1β and IL-18 are its main 
substrates (Martinon et al. 2009). Under certain conditions, activation of caspase 1 
leads to a particular type of programmed cell death termed “pyroptosis”, that, in 
contrast to the silent apoptosis, is associated with a high inflammatory state. 
Pyroptosis is initiated by a variety of stimuli, including cytosolic flagellin, 
phagocytosis of crystals and opening of pores in the membrane and, as 
oncosis/necrosis, it results in the lysis of the cell and release of cytosolic contents 
(Miao et al. 2011; Majno and Joris 1995).  
Four inflammasome complexes have been partially characterized to date. While 
NLRP1 and NLRC4 seem to recognize only specific bacterial components, so being 
involved only in the inflammatory sepsis cascade, the AIM2 and NLRP3 
inflammasomes assemble also in response to endogenous signals, thus playing a role 
also in sterile inflammation (Bauernfeind et al. 2011). 
To date, the NLRP3 inflammasome is by far the best-characterized one and its 
dysregulation has been associated with many disorders, including kidney and liver 
diseases. 
 
1.3.1 The NLRP3 inflammasome  
 
The NLRP3 inflammasome, also known as cryopirin or NALP3, is composed by 
the sensor NLRP3, the adapter protein ASC and the protease caspase1 (Figure 3).  
NLRP3 is expressed primarily in macrophages and dendritic cells (Schroder and 
Tschopp 2010), but also in cells of non-hematopoietic tissues, including epithelial 
cells and osteoblasts (McCall et al. 2008). 
A role for NLRP3 inflammasome in recurrent and chronic inflammation was 
initially described in a group of rare autoinflammatory conditions, termed cryopyrin-
associated periodic syndrome (CAPS), characterized by NLRP3/CIASI mutations 
that cause spontaneous activation of the NLRP3 inflammasome complex leading to 
excessive IL-1β secretion (Agostini et al 2004) and associated sterile inflammation. 
Subsequently, inflammasomes have been implicated in the pathology of many 
common diseases, including cancer, gout and diabetes (Cook et al. 2010). 
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The initial priming step (signal 1), required for subsequent NLRP3 inflammasome 
activation, can be mediated by various PRRs-ligands (both PAMPS and DAMPs) 
and inflammatory cytokines, including LPS, CpG, and TNF-α (Guarda et al. 2011). 
Priming induces activation of NF-kB and is crucial not only to produce a pool of pro-
IL-1β substrate, but also to boost NLRP3 expression to a functional level 
(Bauernfeind et al. 2009, Franchi et al. 2009).  
Several microbial and non-microbial stimuli, associated with both infectious and 
non-infectious diseases, are known to trigger NLRP3 inflammasome activation 
acting as signal 2. The microbial stimuli include cell wall component and toxin 
derived from bacteria and fungi. In addition, the NLRP3 inflammasome is able to 
sense viral RNA and adenoviral DNA, thus playing a role in the control of viral 
infections (Zambetti et al. 2012).  
Non-microbial activators include both particulate exogenous compounds, like 
asbestos fibers or silica, that provoke inflammatory disorders such as silicosis and 
asbestosis, and many DAMPs produced by host damaged cells and associated with 
several diseases. For example, in pathological conditions, injured or necrotic cells 
release high levels of adenosine triphosphate (ATP) that acts as danger signal. 
Moreover, the causative agent of osteoarthritis, i.e., the basic calcium phosphate 
crystals, seems to play a role in NLRP3 inflammasome activation and IL-1β 
secretion (Martinon et al. 2006). Likewise, fibrillar amyloid-β, involved in the 
pathogenesis of Alzheimer’s disease, as well as serum amyloid A (SAA), a crucial 
acute-phase protein in amyloid A-type amyloidosis, are both able to activate caspase 
1 via NLRP3 inflammasome (Niemi et al. 2011, Salminen et al. 2008). Even the 
adjuvant properties of aluminum hydroxide (alum) have been shown to depend on 
activation of the NLRP3 inflammasome (Eisenbarth et al. 2008).  
Moreover, recent papers have reported a crucial role for the NLRP3 
inflammasome in several metabolic diseases, such as gout, atherosclerosis, type 2 
diabetes (T2D) and obesity (De Nardo and Latz 2011). 
Gout, historically known as a ‘disease of kings’ as it is thought to result from a 
diet rich in purines, is a chronic inflammatory condition related to the deposition in 
the joints of uric acid crystals or monosodium urate, MSU. These compounds act as 
NLRP3 inflammasome danger signals causing the release of IL-1β and the 
inflammatory responses in joints (Martinon et al. 2006). 
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Likewise, atherosclerosis is a chronic inflammatory disease characterized by the 
accumulation of lipid components, particularly low density lipoproteins (LDLs), 
within the intima of the artery wall, where they are modified (e.g. oxidized). 
Accumulation of modified LDLs promotes both recruitment of monocytes, with the 
subsequent formation of cholesterol-engorged macrophage foam cells, and the 
formation of cholesterol crystals (Duewell et al. 2010, Klinkner et al. 1995). 
Interestingly, it has recently shown that modified LDLs function as signal 1 
increasing the expression of pro- IL-1β in macrophages via a receptor complex 
involving various TLRs (Stewart et al. 2010) and scavenger receptors (Febbraio et al. 
2000), while cholesterol crystals act as activator molecules of the NLRP3 
inflammasome (Duewell et al. 2010). 
Moreover, a role for the NLRP3 inflammasome in the T2D onset and progression 
has been proposed, since IL-1β promotes beta-cell dysfunction and cell death 
directly (Mandrup-Poulsen et al. 2010). It was demonstrated that the islet amyloid 
polypeptide (IAPP or amylin), a hormone secreted together with insulin, is deposited 
in the islet interstitium of patients with type 2 diabetes and forms amyloid structures 
able to activate the inflammasome (Westermark et al. 2011, Masters et al. 2010). 
Other studies have also suggested that high glucose concentrations induce β-cell 
production and release of IL-1β in vitro, which in turn promotes functional 
impairment and apoptosis of the β-cells in an autocrine manner (Maedler et al. 2002). 
Furthermore, several evidences link insulin homeostasis to NLRP3 inflammasome 
activation, since glyburide, a widely used therapeutic insulin secretagogue, can 
inhibit NLRP3 inflammasome–mediated caspase-1 activation and the release of both 
IL-18 and IL-1β (Lamkanfi et al. 2009). Moreover, mice knock out for any of the 
constituents of the NLRP3 inflammasome fed a high-fat diet (HFD), show improved 
glucose tolerance and insulin sensitivity, linking the NLRP3 inflammasome to 
insulin resistance (Wen et al. 2011, Stienstra et al. 2011, Zhou et al. 2010, Stienstra 
et al. 2010, Vandanmagsar et al. 2010). 
It has long been postulated that obesity is a strong risk factor for insulin resistance 
and type 2 diabetes (Hotamisligil 2006). Notably, recent studies have found that 
obesity itself induces the assembly of the NLRP3 inflammasome in adipose tissue 
macrophages, mediating insulin resistance in early T2D (Vandanmagsar et al 2010, 
Stienstra et al. 2010). Several endogenous danger signals have been implicated in 
NLRP3 activation during obesity, including the lipotoxic ceramide and the saturated 
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fatty acid palmitate, whose circulating levels of both are strongly increased in obesity 
(Wen et al. 2011, Vandanmagsar et al. 2011). 
 
1.3.2 Models for NLRP3 inflammasome activation 
 
As NLRP3 inflammasome can be activated by a broad range of microbial and 
non-microbial compounds, it seems unlikely that such different molecular structures 
could all interact directly with NLRP3 protein. Until now, no NLRP3 activators have 
been indeed shown to directly interact and activate it, suggesting that NLRP3 may 
sense these signals indirectly.  
To date, the mechanisms upstream of NLRP3 inflammasome activation are not 
fully elucidated. Based on the structural and biological characteristic of the activators 
so far identified, three models not mutually exclusive have been proposed (Figure 4). 
In the first model, extracellular ATP activates NLRP3 inflammasome through the 
engagement of the purinergic receptor 2X7 (P2X7R). This binding triggers cellular 
K+ efflux inducing recruitment of the pannexin-1 membrane pore that in turn allows 
extracellular NLRP3 agonists to access the cytosol and activate NLRP3 (Kanneganti 
et al. 2007). 
A second models was proposed to explain the inflammasome activation mediated 
by particulate compounds, including MSU, cholesterol crystal, silica, asbestos, 
amyloid-β, and alum. Based on this mechanism, the engulfment of these molecules 
by phagocytes results either in the failure of the phagocytosis, a process termed 
“frustrated phagocytosis”, or in the rupture of the lysosome membrane within the 
cells, with the consequent release of the lysosomal contents in the environment or 
into the cells respectively. The lysosomal components, particularly the protease 
cathepsin B, in turn could act as activator of the inflammaome (Halle et al. 2008, 
Hornung et al. 2008). 
Finally, the third model, considered also the unifying mechanism, is based on the 
evidences that all NLRP3 activators induce reactive oxygen species (ROS) 
generation and that ROS are able to activate NLRP3 inflammasome. Several studies, 
moreover, have shown that NLRP3 inflammasome activation induced by particulates, 
ATP, nigericin, and yeast can be abrogated by ROS scavengers, suggesting that ROS 
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may act upstream of NLRP3 activation (Zambetti et al. 2012). ROS mainly originate 
by two major processes: the oxygen metabolism in the electron transport chain 
within the mitochondria and the activity of cellular enzymes such as NADPH 
oxidases, xanthine oxidoreductases, lipoxygenases and cyclooxygenases (Dröge et al. 
2002). Several enzymes displaying anti-oxidant activities, including thioredoxin 
(TRX), superoxide dismutases, glutathione peroxidases and catalase are involved in 
neutralizing ROS. Indeed, ROS are important regulators of several physiological 
responses, including angiongenesis, cell growth and differentiation as well as innate 
immune responses (Martinon 2010), but an unbalance between ROS generation and 
neutralization can triggers the harmful oxidative stress, common denominator of 
many diseases, including atherosclerosis and diabetes (Valko et al. 2007). The exact 
mechanism that drives ROS-mediated inflammasome activation remains debated, 
though, recently, Zhou and collegues have demonstrated a direct interaction between 
NLRP3 and TRX-interacting protein (TXNIP). Inflammasome activators, including 
uric acid crystals and hydrogen peroxide, induce the dissociation of TXNIP from 
TRX in a ROS- sensitive manner and allow it to bind and activate NLRP3 (Zhou et 
al. 2010). However, ROS appear to be necessary but not sufficient to mediate this 
process, since a number of signals which generate ROS do not activate the NLRP3 
inflammasome. 
Recently, a major role for ATP and purinergic signal in the NLRP3 
inflammasome regulation has been proposed (Gombault et al. 2012). ATP is in fact 
also considered an extracellular messenger able to act both in autocrine and paracrine 
manner, regulating many physiological and pathological processes through the 
binding to purinergic receptors (Pellegatti et al. 2005). In addition to passive ATP 
release from necrotic cells, to date it results clear that in some cell types, such as 
human monocytes, ATP can be released actively by several NLRP3 activators, 
including MSU, silica, alum crystals, and amyloid-β protein aggregates (Riteau et al. 
2012). On the other hand, ATP leakage from dying autophagic cells and from 
phagocytosis-associated regurgitation by macrophages appears to be important for 
NLRP3 inflammasome activation (Gombault et al 2012).  
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Figure 4. NLRP3 Inflammasome Activation Three major models for NLRP3 inflammasome 
activation are favored in the field, which may not be exclusive: (1) The NLRP3 agonist, ATP, triggers 
P2X7-dependent pore formation by the pannexin-1 hemichannel, allowing extracellular NLRP3 
agonists to enter the cytosol and directly engage NLRP3. (2) Crystalline or particulate NLRP3 
agonists are engulfed, and their physical characteristics lead to lysosomal rupture. The NLRP3 
inflammasome senses lysosomal content in the cytoplasm, for example, via cathepsin-B-dependent 
processing of a direct NLRP3 ligand. (3) All danger-associated molecular patterns (DAMPs) and 
pathogen-associated molecular patterns (PAMPs), including ATP and particulate/crystalline 
activators, trigger the generation of reactive oxygen species (ROS). A ROS-dependent pathway 
triggers NLRP3 inflammasome complex formation. Caspase-1 clustering induces autoactivation and 
caspase-1-dependent maturation and secretion of proinflammatory cytokines, such as IL-1β and IL-18 
(Schroder and Tschopp 2010). 
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1.4 ATP as extracellular messenger  
 
ATP has several features that make it an ideal extracellular messenger: the very 
low extracellular levels under quiescent conditions, the high cytosolic concentration, 
the quick release in pericellular environment caused by many different stimuli, the 
fast degradation in the extracellular space by enzymes expressed on the cell surface, 
and the presence of specific receptors (Burnstock et al. 2007). 
The cytosolic concentration of ATP in mammalian cells is rather high: the 
cytoplasm of most neurons contains 2–5mM ATP, and higher concentrations of ATP 
(up to 100 mM) are stored in synaptic vesicles. Sperm, tumor cells, and the epithelial 
cells of the lens of the eye have exceptionally high intracellular levels of ATP and 
granules in adrenal chromaffin cells, Merkel cells, platelets, and pancreatic insulin-
containing cells also contain significant amounts of nucleotide (Novak 2003).  
ATP efflux from diverse cell types may be elicited by a variety of stimuli, 
including hypoxia, acidosis, mechanical deformation, hyposmotic shock, receptor 
stimulation, fluid shear stress, and membrane depolarization. (Beigi  et al. 1999)  
Responses elicited by this nucleotide range from chemotaxis to cell adhesion, 
cytokine release to neurotransmitter secretion, activation of apoptosis to stimulation 
of cell proliferation (Pellegatti et al. 2005).  
 
1.4.1 ATP release 
 
There are three general mechanisms by which intracellular ATP can be released to 
extracellular spaces.  
• The first involves direct, nonspecific cytolysis of healthy cells by 
physical and biological traumas. In the case of cellular damage, high amounts 
of nucleotides are secreted and such release represents a danger signal that 
stimulates the inflammatory response and the repair mechanisms; 
• A second mechanism involves the release of ATP compartmentalized 
within exocytosis-competent granules or vesicles. ATP is co-packaged in the 
secretory granules of many neuronal, neuroendocrine, or endocrine cells and 
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is rapidly released during synaptic neurotransmission and other types of 
regulated exocytosis;  
• A third potential route for ATP release is the efflux of cytosolic ATP 
via plasma membrane transport proteins. (Beigi et al. 1999).  
 
1.4.2 ATP breakdown 
 
In the extracellular space, the concentration of ATP is regulated by ectoenzymes, 
enzymes expressed on the cell surface whose catalytic site faces the extracellular 
milieu, such as: 
• ectonucleoside triphosphate diphosphohydrolases (E-NTPDasi), that 
degrade both ATP and adenosine diphosphate (ADP) to adenosine 
monophosphate (AMP) and inorganic phosphate;  
• ectonucleotidepyrophosphatases/phosphodiesterases (E-NPP), that 
degrade ATP to AMP and pyrophosphate; 
• alkaline phosphatase, that remove phosphate groups from many types of 
molecules, including nucleotides.  
AMP is then hydrolyzed by 5′ -nucleotidase to generate adenosine (Solini et al. 
2005). 
 
These enzymes maintain the concentration of ATP in the extracellular fluids at 
very low levels in the order of 5-20 µM. 
 
Once the ATP molecule is released into the extracellular milieu, ATP, as an 
agonist, can bind to two subclasses of P2 purinergic receptors: the P2Y G-protein-
coupled receptors and the P2X receptor channels (Schwiebert 2001). 
 
 
 
 
	   21	  
1.5 Purinergic receptors  
 
Purinergic receptor, or purinoceptor, are a family of receptors (P1 and P2) 
classified according to their molecular structure and to the relative potency of purine 
nucleotides and nucleosides in stimulating them.  
P1 receptors are G protein-coupled receptors also known as adenosine receptors 
(ARs) for their ability to bind this nucleoside and are divided into four subtypes: 
A1R, A2AR, A2BR, and A3R (Ralevic and Burnstock 1998). Adenosine 
accumulates in the extracellular space in response to metabolic stress, cell damage 
and in conditions of ischaemia, hypoxia, inflammation and trauma (Haskó et al. 
2008).  
P2 receptors are activated by extracellular nucleotide and are further divided into 
two major families, a P2Y family of G-protein-coupled receptors ( P2YR) and a P2X 
family of ligand-gated ion channel receptors ( P2XR). The native agonist for P2XRs 
is ATP, whereas both ATP and its metabolite ADP act as agonists for P2YRs in a 
receptor-specific manner. Other endogenous nucleotides, such as UTP, UDP, and 
UDP-glucose, are potent agonists for some P2YRs, but they have no activity on 
P2XRs (Jacobson and Gao 2006). 
 
1.5.1 P2X receptors  
 
P2XRs are nonselective cation-conducting channels present in multiple species, 
from unicellular organisms to humans. ATP binds to and activates purinergic 2X 
receptors, thus causing transmembrane calcium, sodium and potassium fluxes, with 
consequent membrane depolarization that may drive further calcium influx (Solini et 
al. 2005). 
Seven mammalian purinergic 2X receptor subunits, denoted P2X1 through P2X7, 
and several spliced forms of these subunits have been identified (North 2002).  
The P2X subunit proteins are 379 (P2X6) to 595 (P2X7) amino acids long. Each 
isoform consists of two membrane-spanning α-helices (TM1 and TM2), the first 
involved with channel gating and the second lining the ion pore; a large extracellular 
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domain (comprising at least 50% of the total molecular mass); and intracellular N- 
and C-termini, possessing consensus binding motifs for protein kinases. From the 
amino terminus to the second transmembrane domain, the isoforms are 37–48% 
identical, with 10 conserved cysteine residues in the extracellular domain of each 
isoform. These cysteines may be important in stabilizing the ATP-binding pocket, 
which may involve regions of the extracellular loop adjacent to TM1 and TM2. 
P2XRs share a similar agonist binding site with some variations in the binding 
pocket or gating, which account for receptor specificity in agonist and antagonist 
binding/receptor gating. Eight residues have the potential to contribute to the 
formation of the ATP binding site: Lys67, Lys69, Phe185, Thr186, Asn293, Phe294, 
Arg295, and Lys313 (P2X4R numbering). Positively charged lysines seem to 
coordinate the binding of the negatively charged phosphate tail of ATP, whereas 
aromatic phenylalanine residues could coordinate the binding of the ATP adenine 
ring directly or indirectly (Surprenant and North 2009).  
The carboxyl terminus of each of the isoforms is the most variable (Burnstock 
2007, Schwiebert 2001). 
P2X receptor subunits can combine to form either homomultimers or 
heteromultimers. Heteromultimers are clearly established for P2X2/3 receptors in 
nodose ganglia, P2X4/6 receptors in CNS neurons, P2X1/5 receptors in some blood 
vessels, and P2X2/6 receptors in the brain stem. P2X7 receptors do not form 
heteromultimers, and P2X6 receptors will not form a functional homomultimer 
without extensive glycosylation. P2X5 receptors will assemble with any others, 
except P2X7. The conserved cysteines in the extracellular domain play also a critical 
role in multimeric association of P2X receptor subunits, conferring a complex three-
dimensional structure (Burnstock 2007, Schwiebert 2001).  
All the P2X receptor subunits have multiple consensus sequences for N-linked 
glycosylation in the extracellular domain (Asn-X-Ser/Thr) considered essential for 
the membrane localization of the subunits. Receptors in which any two of the three 
sites are glycosylated, indeed, appear at the cell surface and are fully functional. 
Receptors in which only one site is glycosylated give barely detectable currents in 
response to ATP, and channels with no sites glycosylated give no current. These 
double and triple mutant receptors are retained within the cell (North 2002). 
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P2X receptors are abundantly distributed, and functional responses are seen in 
neurons, glia, epithelia, endothelia, bone, muscle, and hemopoietic tissues. On 
smooth muscles, P2X receptors respond to ATP released from sympathetic motor 
nerves. On sensory nerves, they are involved in the initiation of afferent signals in 
several viscera (e.g., bladder, intestine) and play a key role in sensing tissue-
damaging and inflammatory stimuli. In the last case, P2X7 receptor activation 
stimulates cytokine release by engaging intracellular signaling pathways (North 
2002).  
 
1.6 P2X7 receptor  
 
The P2X7R subunit, initially cloned from a rat brain cDNA library, shares an 
overall membrane topology with the other members of this family of receptors, 
consisting of two transmembrane domains connected by a large extracellular loop. 
The extracellular loop contains conserved cysteine, lysine, and glycine residues 
along with a number of potential N-linked glycosylation sites, all of which contribute 
to the structural constraints required for ATP binding (Jiang et al. 2000, Surprenant 
et al. 1996). The receptor is distinguished structurally from other members of P2XRs 
by its long intracellular C terminus tail (240 amino acids, 120 amino acids longer 
than any of the other P2X members) containing multiple protein and lipid interaction 
motifs and a cysteine-rich 18 amino acid segment (Coddou et al. 2011). Denlinger 
and coworkers, indeed, have identified several sites homologous to those known to 
be involved in the binding of LPS, TNF and SH3 domain (Denlinger et al. 2001). 
This long C-terminal domain appears to modulate the function of the P2X7R, because 
the removal of this region blunts the receptor’s response to ATP. Moreover, the 
region from residues 551 to 581 participate in regulating the surface expression of 
the P2X7R (Figure 5). 
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Figure 5.The P2X7R: membrane topology. TNF RI homology domain (green) and putative LPS 
binding region (red) are shown. Cysteine residues forming putative disulfide bridges are also shown 
(Adapted from Ferrari et al. 2006).  
 
 
 
Although originally thought to be predominately expressed on cells of 
hemopoietic lineages, it is emerging that the P2X7 receptor has a ubiquitous 
distribution (Burnstock and Knight 2004), despite that, its expression levels may vary 
over orders of magnitude. P2X7R is present in greatest amounts on macrophages 
followed by dendritic cells, monocytes, natural killer cells, lymphocytes and 
erythrocytes in descending order (Gu et al. 2004, Gu et al. 2000). P2X7R is also 
present on mast cells, eosinophils, osteoclasts and microglia, while neutrophils 
showed no surface expression of P2X7 receptors but do contain intracellular receptors 
(Gu et al. 2000). Finally, P2X7 is also expressed on cells of non-hematopoietic origin 
including bone cells, epithelial cells from the skin, kidney, reproductive and urinary 
tracts (Burnstock and Knight 2004), fibroblasts (Solini et al. 1999), endothelial cells 
(Wilson et al. 2007), exocrine glands (salivary glands and pancreas) (Novak 2008) as 
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well as glomerular cells, mainly podocytes but, to a lesser degree, also endothelial 
and mesangial cells (Vonend et al. 2004). 
P2X7R is the least sensitive member of the P2XR family to activation by 
nucleotides. It is activated by extracellular ATP (EC50 > 80 – 100 μM) and the more 
potent ATP analogue, 2′ ,3′ -(benzoyl-4-benzoyl)- ATP, (BzATP) (EC50 = 7 μM) 
(Surprenant et al. 1996). Other analogues like 2-meSATP and ATPγS are partial 
agonists of this receptor, whereas αβ-meATP and βγ-meATP have very little effect 
on activation. These analogs are metabolically more stable than ATP being relatively 
resistant to breakdown by ectonucleotidases. A few years ago, Kim and collegues 
(Kim et al. 2001) showed that the P2X7 receptor becomes dephosphorylated on Tyr-
343 as a result of exposure to agonist. The direct demonstration that the P2X7 
receptor complex in HEK293 cells contains a receptor protein tyrosine phosphatase 
(RPTP β) favors the interpretation that this is activated when ATP binds to the 
receptor and exert a feedback control of the channel itself through its 
dephosphorylation.  
Several compounds act as P2XR antagonists. The first functional studies of P2X 
receptors were based on the evidence from the broad inhibitory effects of suramin, an 
agent introduced almost a century ago for the treatment of trypanosomiasis, of 2′ ,3′ 
-dialdehyde ATP (oxidized ATP), and pyridoxalphosphate-6- azopheny-2′ ,4′ -
disulfonate (PPADS). However, these compounds are not specific for P2X7R (Hibell 
et al. 2001, Surprenant et al. 1996). The first relatively specific P2X7R antagonist 
identified was KN-62; however, it blocks currents in cells expressing the human P2X7 
receptor but has little effect on the rat P2X7R (Humphreys et al. 1998) and at high 
concentrations it also blocks Ca2+ /calmodulin-dependent protein kinase II. Selective 
antagonists of P2X7R activation have only recently become available. Two of these 
antagonists, A-438079 and A-740003, have been shown to impair nociception in 
rodent models of neuropathic and inflammatory pain (Donnelly-Roberts and Jarvis 
2007). These in vivo findings support therapeutic trials of P2X7R blockers, and at 
least two P2X7R antagonists, CE-224535 (Pfizer) and EVT 401 (Evotec), are 
currently undergoing various phase I or II trials. In addition to chemical antagonists, 
the anti-human P2X7R mAb (clone L4) can impair human P2X7R function including 
P2X7R-induced cation fluxes and IL-1β release (Buell et al. 1998).  
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P2X7R activation is also inhibited by many divalent cations with a rank potency of 
Cu2+ > Cd 2+ = Zn2+ > Ni2+>> Mg2+ = Co2+ > Mn2+ > Ca2+ = Ba2+ >> Sr2+ (North 
2002). Some of the divalent cations may function by altering the affinity of ATP 
binding to P2X7R (Jiang 2009) (acting as allosteric modulators) or by making 
complexes with ATP, reducing the free acid form of ATP (or ATP4-) in solution. 
Agonist binding to the P2X7 receptor opens a non-selective cation channel 
permeable to both monovalent (Na+, K+) and divalent (Ca2+, Sr2+, Ba2+ ) cations 
causing plasma membrane depolarization. The intrinsic ion channel opens rapidly 
within milliseconds of agonist binding, and there is little or no rectification nor 
desensitisation of inward currents as measured by electrophysiology (North 2002, 
Surprenant et al. 1996). 
One of the most defining and peculiar characteristics of P2X7R, which follows 
activation of the receptor when the agonist application is prolonged or repetitive, is 
the slow development over tens of seconds of a secondary permeability pathway or 
‘pore’ that permits the entry into cells of large organic molecules up to 900 Da and 
the leakage of metabolites (a process known as cell “permeabilization”). This pore 
pathway can be measured using or propidium dyes such as ethidium+ (314 Da) or 
YO-PRO-12+ (375 Da), that become fluorescent when they intercalate nucleic acids, 
giving a direct measure of their entry into cells (Wiley et al. 2011). 
A key question that is raised is whether these two properties, i.e., the opening of a 
selective cation channel and the later formation of non-selective pores, are intrinsic 
to the P2X7 receptor protein or whether they require additional molecules to be 
provided by the host cell. 
At least two conflicting hypotheses have been postulated to reconcile these 
findings (Yan et al. 2010):  
(1) the pore-dilation hypothesis suggests that there is a progressive dilation of the 
cation-conducting pore from initially 7Å up to 40Å; 
(2) the two-pore hypothesis implies the activation of an endogenous P2X7R pore 
permeable for inorganic cations, accompanied by sustained activation of a distinct 
channel permeable to larger organic cations and fluorescent dyes. 
The finding that the P2X7R-dependent fluorescent dye uptake correlates with 
recruitment of pannexin-1 hemichannels (Pelegrin and Surprenant 2006) or a 
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modulation of the multidrug transporter P-glycoprotein (Elliott et al. 2005) support 
the second hypothesis. On the other hand, Yan and collegues have recently shown 
that naive rP2X7R activates and deactivates biphasically at higher agonist 
concentrations, and the slow secondary growth of current coincides with pore 
dilation. The generation of biphasic currents is not blocked by inhibition of 
pannexin-1 channels and is also observed in cells not expressing pannexins (Yan et 
al. 2008). Conversely, this response is abolished by the application of a P2X7R-
specific antagonist (Yan et al. 2010), supporting the pore-dilation hypothesis.  
In 1996 Surprenant and colleagues (Surprenant et al. 1996) demonstrated the 
importance of the C-terminal tail in the formation of the pore membrane. Indeed, the 
truncated form of the receptor to residue 418 (P2XΔC) is unable to make the 
transition channel-pore. Experiments conducted with truncated P2X7 receptors 
expressed in HEK293 and in oocytes of Xenopus have demonstrated the importance 
of at least 582 amino acids for the activation of the pore, otherwise, the channel 
formation occurs even if the receptor is truncated at position 380. Thus, unlike the 
pore, the formation of the channel requires a small portion of the intracytoplasmic 
tail (Smart et al. 2003). It is therefore clear that further analysis will be needed to 
clarify the mechanism of channel-pore transition.  
 
1.6.1 P2X7R and kidney and liver disease 
 
Recent studies using P2X7R-/- mice and specific receptor antagonists have 
associated P2X7R with the onset and development of several disorders, including 
renal, neurological, rheumatological and respiratory diseases. 
Regarding the kidney, previous studies have shown the functional differentiation 
of P2XRs and P2YRs in the modulation of mesangial cell and extracellular matrix 
(ECM) turnover. The P2XRs, especially P2X7R and P2X4R, were found to promote 
mesangial cell apoptosis (Solini et al. 2007, Harada et al. 2000) and favor glucose-
induced ECM synthesis (Solini et al. 2005), whereas the P2YRs, likely P2Y2R and 
P2Y4R, were shown to induce mesangial cell proliferation (Harada et al. 2000) and to 
inhibit matrix production (Solini et al. 2005).  
Furthermore, P2X7R was found to be up-regulated in glomeruli of diabetic and 
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hypertensive rats (Vonend et al. 2004) and, more recently, it has been implicated in 
two experimental models of inflammatory renal injury, i.e. unilateral ureteral 
obstruction (UUO) (Gonçalves et al. 2006) and antibody-mediated 
glomerulonephritis (Taylor et al. 2009). Gonclaves and coworkers demonstrated that 
the tubulo-interstitial damage and subsequent fibrosis associated with UUO were 
attenuated in P2X7R-/- mice, suggesting a role for tubular P2X7R in renal 
inflammation and fibrosis. Moreover, Taylor et al. provided strong evidence for a 
pathogenic role of P2X7R in a rodent model of experimental glomerulonephritis 
(GN) and demonstrated that P2X7R-/- mice were significantly protected from 
antibody-mediated GN (Taylor et al. 2009, Turner et al. 2007). 
Although P2X7R was found to be up-regulated in glomeruli of diabetic and 
hypertensive rats (Vonend et al. 2004), there is no in vivo evidence for the 
involvement of the P2X7R in the onset and progression of chronic kidney disease 
(CKD) associated to metabolic disorders. However, it has been shown that both 
glucose and free fatty acids (FFAs) rapidly up-regulate P2X7R in human islets (Glass 
et al. 2009), thus suggesting a role for dyslipidemia in P2X7R modulation. 
Less clear is the involvement of P2X7R in the pathophysiology of liver diseases. 
However, recent evidence suggests that this receptor might be implicated in liver 
injury induced by acetaminophen (APAP) (Hoque et al. 2012). In detail, P2X7R-/- 
mice as well as wild type mice treated with the specific P2X7R antagonist A438079 
had significantly decreased APAP-induced liver necrosis and hemorrhage. Chatterjee 
and colleagues, moreover, suggested that in the liver P2X7R could participate in the 
onset of the inflammatory response to carbon tetrachloride poisoning through the 
activation of NADPH oxidases, thus demonstrating a P2X7R -NADPH oxidase axis  
in liver steatosis and fibrosis (Chatterjee et al. 2012).  
 
1.6.2 P2X7R and innate immunity 
 
Among P2X receptors, P2X7R is characterized by the cross-talk of its downstream 
signaling with the pro-inflammatory cascades (North 2002). 
In response to ligand binding a variety of downstream events follows, including 
activation of the NF-kB, processing and secretion of pro-inflammatory IL-1β and IL-
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18, microvesicle/exosome release and apoptosis of the cell (Wiley et al. 2011). 
Since the cytoplasmic ATP concentration is in the millimolar range, cell injury or 
death mediated by both infectious and sterile stimuli cause massive ATP release into 
the extracellular milieu. Interacting with P2X7R expressed by resident cells, both 
parenchymal and immune resident cells (i.e., the reticuloendothelial system), ATP 
participates in the activation of pro-inflammatory signals that trigger the recruitment 
of circulating inflammatory cells. However, there is also compelling evidence for 
non-lytic ATP secretion via as yet unidentified pathways activated by host- or 
pathogen-derived factors (Ferrari et al. 2006). 
 
1.6.3 P2X7R and reactive oxygen release  
 
Nicotinamide adenine dinucleotide phosphate-oxidase (NADPH ox) is a 
membrane-bound enzyme complex that catalyzes the production of superoxide from 
oxygen and NADPH. For a long time, superoxide generation by an NADPH ox was 
considered a function restricted to professional phagocytes. Over the last years, six 
homologs of the cytochrome subunit of the phagocyte NADPH ox were found: 
NOX1, NOX3, NOX4, NOX5, DUOX1, and DUOX2. These enzymes share the 
capacity to transport electrons across the plasma membrane and to generate 
superoxide and other downstream reactive oxygen species (ROS). Activation 
mechanisms and tissue distribution of the different members of the family are 
markedly different. The physiological functions of NOX family enzymes include 
host defense, post-tranlational processing of proteins, cellular signaling, regulation of 
gene expression, and cell differentiation. NOX enzymes also contribute to a wide 
range of pathological processes. Interestingly, as mentioned above, it has recently 
shown that the P2X7 receptor is a primary mediator of oxidative stress-induced 
exacerbation of inflammatory liver injury in obese mice via NADPH oxidase-
dependent mechanisms (Chatterjee et al. 2012) 
In the kidney, the Nox4 isoform was first identified in the early 2000s and was 
originally described as an oxygen sensor and regulator of kidney cell growth and 
because of its renal abundance was termed “renox”. However, some data point to a 
role for Nox4 as the major source of ROS in the kidneys during early stages of 
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diabetes and establish that Nox4-derived ROS mediate renal damage and 
inflammation/fibrosis (Gorin et al. 2005). To date, it is not known if a P2X7 receptor-
NADPH oxidase axis is also present in the kidney and if it plays a role in renal 
damage associated to MS. 
 
1.6.4 P2X7R and NF-kB 
 
NF-kB is a transcription factor found in almost all animal cell types and plays a 
key role in regulating the immune response to infection. The ATP -but not other 
nucleotides- binding to P2X7 receptor leads to the activation of NF-kB. The subunit 
composition of the ATP-induced NF- kB–DNA complex is rather unusual, resulting 
in the sole appearance of a p65 homodimer, that is probably involved in the 
regulation of specific inflammatory and apoptotic target genes. This ATP-induced 
activation requires reactive oxygen intermediates (ROIs) and proteasome and 
caspase-1 proteolytic activity (Ferrari et al. 1997).  
Recently, Liu and collegues have demonstrated that P2X7R is involved in the 
activation of NF-kB mediated by LPS and ATP, thus suggesting the involvement of 
this purinergic receptor in the initiation of the NF-kB-dependent inflammatory events 
triggered by both infections and cell damage per se (Liu et al. 2011). 
 
1.6.5 P2X7R and NLRP3 inflammasome 
 
As mentioned above, it is known that activation of the P2X7 receptor has a central 
role in the innate immune responses through the secretion of pro-inflammatory 
interleukin IL-1β and IL-18 from cells of myeloid origin (Wiley et al. 2011). Early 
observations showed that extracellular ATP is a strong IL-1β-releasing agent 
(Griffiths et al. 1995, Perregaux and Gabel 1994); subsequent in vitro “loss of 
function” and “gain of function experiments”, together with in vivo analysis 
conducted on P2X7R-/- mice, made it possible to establish that the receptor 
responsible for ATP-dependent IL-1β release is the P2X7R (Solle et al. 2001, Ferrari 
et al. 1997, Ferrari et al. 1996). Mechanistically, the role of K+ efflux in supporting 
P2X7R-dependent IL-1β processing and release seems to be crucial as both processes 
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are suppressed by inhibition of cellular K+ efflux (Ferrari et al. 1997, Perregaux and 
Gabel 1994). Consistently, mutations in the human P2X7R that impair both pore 
formation and ATP-stimulated K+ efflux inhibit IL-1β and IL18 release (Sluyter et al. 
2004), and several stimuli that also cause a rapid lowering of cytoplasmic K+ , e.g. 
the ionophore nigericin or sucrose medium, induce robust IL1β processing. 
(Kahlenberg and Dubyak 2004, Sanz and Di Virgilio 2000, Ferrari et al. 1997). In 
addition to K+ efflux from the cell, after P2X7R activation there is an influx of Ca2+, 
which is also required for the release of active IL-1β (Ferrari et al. 2006, MacKenzie 
et al. 2001). 
 
Also based on the evidence that cellular K+ efflux and increased intracellular Ca2+ 
concentration are crucial for NLRP3 activation, a mechanistic link between P2X7R 
and NLRP3 activity in the regulation of cytokines release was suggested 
(Mariathasan et al. 2006). In detail, it was shown that eATP activates the NLRP3 
inflammasomes through P2X7R (Bours et al. 2011), and that P2X7R -dependent IL-
1β secretion requires assembly of a fully functional inflammasome since mice 
deficient in the adaptor protein ASC fail to process pro-IL-1β in response to ATP 
(Qu et al. 2007, Mariathasan et al. 2006). Therefore, in response to ATP binding, the 
P2X7 receptor would induce inflammasome assembly and caspase 1 activation 
(Martinon 2008). However, the observation that LPS-primed macrophages from 
transgenic mice lacking P2X7 receptors are unable to release IL-1β, but retain the 
ability to increase the synthesis of pro-IL-1β and caspase-1 in response to ATP- that 
is an NF-kB-dependent response (Labasi et al. 2002 , Solle et al. 2001)-suggest that 
P2X7R is essential for NLRP3 activation but is dispensable for NLRP3 priming. 
However, it is currently debated whether also extracellular ATP needs a priming 
signal or if it is a sufficient stimulus to induce both synthesis and activation of the 
NLRP3 inflammasome complex.  
Furthermore, Pelegrin and Surprenant showed that signalling through pannexin-1 
is required for processing of caspase-1 and releasing of mature IL-1β induced by 
P2X7 receptor activation (Pelegrin and Surprenant 2006). The same group have 
proposed a model for the P2X7R-mediated NLRP3 activation by which pannexin-1-
pore formation, resulting from prolonged activation of P2X7R, allows entry of 
bacterial products (PAMPs), DAMPs and extracellular ATP into the cell, which 
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directly activate inflammasome (Pelegrin and Surprenant 2009). Although the 
structural diversity within NLRP3 agonists argues against direct interaction between 
NLRP3 and all of its activators, it is not possible to exclude that the P2X7R-mediated 
pannexin-1-pore formation could somehow facilitate the engagement of NLRP3 by 
its activators. 
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The innate immune system is involved in the pathogenesis of metabolic disorders, 
since it is now well-known that a state of low-grade chronic inflammation 
characterizes central obesity and plays a pivotal role in the development of the 
metabolic syndrome (MS) and type 2 diabetes, as well as in the complications of 
these disorders, including kidney and liver disease. However, to date, the molecular 
basis of activation of renal and liver pro-inflammatory and fibrogenic signaling 
pathways involved in this condition is still poorly defined. 
The P2X7 receptor is a purinergic receptor whose pro-inflammatory role is well 
established. Upon activation by its ligand ATP, several downstream events follow, 
including secretion of pro-inflammatory interleukins and apoptosis of the cell. 
Importantly, a mechanistic link between P2X7R and NLRP3 activity in the regulation 
of cytokines release has been recently demonstrated. However, to date, P2X7R and 
NLRP3 have been only associated with tissue damage induced by inflammatory 
diseases mediated by microbial pathogens, auto-immune diseases or models of acute 
injury, whereas their role in the onset and progression of complications of MS is 
unknown. 
 
This study was aimed at investigating the contribution of the purinergic receptor 
2X7 in the process driving renal/liver inflammation and injury associated with the 
MS and type 2 diabetes. To this end, P2X7R-deficient (P2X7R-/-) mice were used to 
examine the participation of P2X7R in the development of renal and liver disease 
induced by an high fat diet (HFD), a well-established experimental model of diet-
induced MS. Mechanistically, this study also investigated the involvement of the 
NLRP3 inflammasome in inflammation and tissue injury induced by the HFD and 
verified whether P2X7R ablation affected the NLRP3 response in this setting, in 
order to identify a P2X7R-NLRP3 axis eventually operating in the pathogenesis of 
these complications of type 2 diabetes and MS. Moreover, P2X7R and NLRP3 
expression analyses were also performed in kidney specimens from human subjects 
with type 2 diabetes. 
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3.1 Animal model 
 
Adult (aged six weeks) male P2X7R-/-  (Glaxo strain) and wild-type (WT mice) 
were kindly provided by Prof. F. Di Virgilio (University of Ferrara, Ferrara, Italy). 
Mice were housed in a germ-free stabularium in accordance with the Principles of 
Laboratory Animal Care (NIH Publication No. 85-23, revised 1985) and received 
water and food ad libitum. The study protocol was approved by the local ethics 
committee. Mice from both genotypes were fed for 16 weeks with either a HFD 
(DIO diet D12492, 60% of total calories from fat) or a normal-fat diet (NFD, DIO 
diet D12450B; 10% of total calories from fat), purchased from Research Diets 
(Mucedola, Settimo Milanese, IT). Each group consisted of seven animals. At the 
end of the 16-week period, mice were placed into metabolic cages to collect urines. 
The next day, they were anaesthetized with intraperitoneal ketamine (Imalgene®, 60 
mg/kg body weight) and xylazine (Rompum®, 7.5 mg/kg body weight) and a 
longitudinal incision of the abdominal wall was performed, a blood sample was 
obtained and both kidneys and liver were removed and weighed. Then, a sagittal 
section of the right kidney and a portion of liver tissue was immediately fixed by 
immersion in phosphate buffered 4% formaldehyde solution and processed for light 
microscopy examination and morphometrical evaluation. Paraffin-embedded sections 
were used also for immunohistochemistry. The remaining tissue from right kidney, 
together with left kidney and additional liver specimens, were frozen in liquid 
nitrogen and used for extraction of cytosolic and nuclear proteins and total RNA 
from renal cortex and liver tissue.  
 
3.2 Human kidneys 
 
Unaffected kidney samples from 6 patients with type 2 diabetes and 3 nondiabetic 
subjects who had undergone unilateral nephrectomy for renal cell carcinoma were 
used for P2X7R, NLRP3 and ASC expression analysis by immunohistochemistry and 
RT-PCR. Samples were also evaluated for the presence and extent of renal lesions 
(see below). 
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3.3 Renal morphology/morphometry 
 
Formalin-fixed and paraffin-embedded sections from mice and human kidneys 
were stained with periodic acid Shiff (PAS). Morphometrical analysis was performed 
by the use of a custom-made, C-language macro written with the Optimas 6.5 image 
analysis system (Optimas Corp, MediaCybernetics, Silver Spring, MD). The 
glomerular tufts considered were subsequent unselected occurrences falling in the 
observation field of the operator who moved the stage in a serpentine fashion from 
the outer cortex to the juxtamedullary region. The areas of at least 60 glomerular tuft 
profiles per sample were measured, the harmonic mean of the profile area (mean 
glomerular area, mGA) was obtained, and the mean glomerular volume (mGV) was 
estimated from it. Then, PAS-positive material in each of these glomeruli was 
quantified and expressed as percentage of the glomerular tuft area (fractional 
mesangial area, fMA). The color threshold was set by identifying three to five 
separate pixels in areas of positive staining. Finally, the mean mesangial area (mMA) 
was calculated by the formula: (fMA x mGA)/100. For the assessment of renal lipid 
accumulation, frozen mice kidney 6 μm sections were immersed in 4% formaldehyde 
for 1 hour, washed with distilled water and stained with oil red O (ORO) solution 
(Sigma, 0.5% in isopropyl alcohol-distilled water solution, 60:40) for 30 min. 
Finally, sections were washed, counterstained with hematoxylin, mounted and 
analyzed. 
 
3.4 Liver morphology/morphometry 
 
Liver morphology was assessed based on the American Association for the Study 
of Liver Disease (AASLD) Guidelines (Neuschwander-Tetri and Caldwell 2003). In 
hematoxylin and eosin-stained sections, steatosis grading was assessed based on the 
percentage of parenchyma involved (grades 0 to 3 as follows: 0, no fat; 1, <33%; 2, 
33-66%; 3, >66%). Steatosis grade and the presence of inflammation (scored 0 to 3 
as follows: 0, no inflammation; 1, mild; 2, moderate; 3, severe), hepatocyte 
degeneration (acidophil or Councilman’s bodies, ballooning and Mallory’s hyaline) 
or necrosis and fibrosis were then considered for nonalcoholic fatty liver disease 
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(NAFLD) classification as follows: Class 1: simple steatosis, predominantly 
microvesicular; class 2 simple steatosis, predominantly microvesicular with scarce 
lobular inflammation; class 3 micro/macrovesicular steastosis with modest lobular 
inflammation and ballooning degeneration; class 4 predominantly macrovesicular 
steatosis, lobular and portal inflammation, balloning degeneration (either Mallory’s 
hyaline or fibrosis). Within this system, class 3 and 4 NAFLD are similar and might 
be considered as a single group constituting NASH. 
Subsequently, samples from NASH (i.e., class 3 and 4 NAFLD) mice was graded 
based on the type of fat (macrovesicular, microvesicular or mixed), and extent of 
inflammation (scored 0 to 3 as follows: 0, no inflammation; 1, mild; 2, moderate; 3, 
severe), and hepatocyte degeneration or necrosis. In detail, Grade 1, mild. Steatosis: 
predominantly macrovesicular, ranges from less than 33% to up to 66% of the 
lobules. Ballooning: occasionally observed; zone 3 hepatocytes. Lobular 
inflammation: scattered and mild acute (polymorphs) and chronic inflammation 
(mononuclear cells). Portal inflammation: none or mild. Grade 2, moderate. 
Steatosis: any degree, usually mixed macrovesicular and microvesicular. Ballooning: 
present in zone 3. Lobular inflammation: polymorphs may be noted associated with 
ballooned hepatocytes, and/or pericellular fibrosis;  mild chronic inflammation. 
Portal inflammation: none, mild to moderate. Grade 3, severe (florid steatohepatitis). 
Steatosis: usually 66% (zone 3 or panacinar); commonly mixed steatosis. Ballooning: 
predominantly zone 3; marked. Lobular inflammation: scattered acute and chronic 
inflammation; polymorphs may appear concentrated in zone 3 areas of ballooning 
and perisinusoidal fibrosis. Portal inflammation: mild or moderate; not predominant 
or marked  
Finally, sections stained with Masson's trichrome were staged for NASH by 
assessing the extent and distribution of fibrosis. 
Stage 1: Zone 3 perivenular, perisinusoidal, or pericellular fibrosis; focal or 
extensive. Stage 2: As for stage 1 plus focal or extensive portal fibrosis. Stage 3: 
Bridging fibrosis, focal or extensive. Stage 4: Cirrhosis with or without residual 
perisinusoidal fibrosis. 
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3.5 Biochemistry and ELISA 
 
Blood samples obtained from experimental animals were analyzed for fasting 
levels of glucose, cholesterol, triglycerides, aspartate and alanine transaminase by 
standard chemical methods (VITROS5.1 FS Chemistry System, Ortho-Clinical 
Diagnostics, Rochester, NY) and insulin by enzyme immunoassay (Ultrasensitive 
Mouse Insulin ELISA kit, Mercodia AB, Uppsala, Sweden); the homeostasis model 
assessment - insulin resistance (HOMA-IR) index was then calculated from fasting 
glucose and insulin. Serum and urine creatinine levels were assessed by HPLC. 
Proteinuria and albuminuria were measured using the Bradford dye-binding protein 
assay kit (Pierce, Rockford, IL) and the Mouse Albumin ELISA Quantitation Kit 
(Bethyl Laboratories, Montgomery, TX), respectively, and results were normalized 
by urine creatinine. The activation of NF-kB/p65 was assessed using the Mercury 
TransFactor NF-kB p65 kit (BD Biosciences Clontech, Palo Alto, CA) (Iacobini et 
al. 2009, Iacobini et al. 2005). Levels of IL-1β and IL-18 in kidneys were measured 
by the use of the Biochip Array Technology (Evidence, Randox Laboratories Ltd, 
Crumlin, Antrim, UK).  
 
3.6 Immunohistochemistry and Western blot analysis 
 
Renal content and distribution of active caspase-3, fibronectin, collagen IV α1 
chain, F4/80, monocyte chemoattractant protein-1 (MCP-1), the renal isoform 4 of 
NAD(P)H oxidase (Nox4), the advanced glycation endproducts (AGEs)/advanced 
lipoxidation endproducts (ALEs) Nε-(carboxymethyl)lysine (CML) and protein 
adducts of 4-hydroxy-2-nonenal (HNE), receptor for AGEs (RAGE), as well as renal 
and liver P2X7R and NLRP3 were assessed by immunohistochemistry.   
Analogously to PAS positivity, the percentage of glomerular area of positive 
staining was calculated by means of the image analysis system Optimas™6.5. A 
region of interest was drown around the glomerulus. Then, the percentage of positive 
area for the specific stain (brown color) was calculated at a fixed color threshold (see 
above). For each kidney specimen, the average for percentage of glomerular area 
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from at least 60 glomeruli was used. For some antigens (F4/80 and MCP-1), positive 
staining was measured in 20 random fields of the renal cortex examined at a final 
magnification of 400X and expressed as the mean percentage of fields area occupied 
by the specific stain. 
Renal cortex levels of caspase-1 were evaluated by Western blot analysis (Solini 
et al. 2007). Primary antibodies used in western blot: rabbit polyclonal antibody to 
caspase 1 (Millipore 06-503) and mouse monoclonal antibody to β-actin (Sigma, 
A5441); Secondary antibodies: Polyclonal Goat Anti-Mouse Immunoglobulins/HRP 
(Dako, P 0447) and Polyclonal Goat Anti-Rabbit Immunoglobulins/HRP ( Dako P 
0448). Bands were detected by enzymatic chemiluminescence kit (Immobilon 
Western, Millipore; Billerica, MA) and quantified by scanning densitometry using a 
GS-670 Imaging Densitometer (Bio-Rad Laboratories, Hercules, CA). Primary 
antibodies used in the immunohistochemistry studies. 
1. rabbit polyclonal antibodies to: 
- P2RX7 (Abcam, ab48871) 
- NLRP3 (Sigma, HPA012878) 
- active caspase-3 (Anti-ACTIVE® Caspase-3, Promega Italia, Milan, Italy); 
- fibronectin (Sigma, F3648); 
- collagen IV (Abcam, ab13966); 
- HNE adducts (Alpha Diagnostic International, San Antonio, TX, USA); 
- recombinant full length rat MCP-1 (Abcam, ab7202); 
- recombinant mouse NOX4-glutathione S transferase (299–515, Prof Abboud 
HE, University of Texas); 
2. goat polyclonal antibodies to: 
- RAGE (Novus Biologicals, ab7764)  ; 
3. rat monoclonal antibodies to: 
- mouse F4/80 (Novus Biologicals, NB 600-404); 
4. mouse monoclonal antibody to: 
- CML (biotinylated) (Wako, Neuss, Germany); 
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Secondary antibodies: 
1. Biotinylated Goat Anti-Rabbit Immunoglobulins (Dako, E0432)  
2. Biotinylated Rabbit polyclonal to Goat IgG H&L (Abcam, ab6740) 
3. Biotinylated Goat polyclonal to Rat IgG H&L (Abcam, ab6844) 
4. Biotinylated Goat polyclonal to mouse IgG H&L (Abcam, ab6788) 
 
3.7 Quantitative real time PCR 
 
Total RNA was extracted from mice renal cortex, human kidney specimens and 
mice liver with the RNAeasy mini kit (Qiagen, Milan, Italy). Then, 1μg of RNA was 
reverse-transcribed in a 20-μl reaction tube using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Monza, Italy). Quantitative PCR was 
performed in triplicate on an ABI PRISM 7900 HT instrument (Applied Biosystems) 
following the standard protocol. Transcripts for fibronectin, collagen IV α1 chain, 
MCP-1, F4/80, collagen I, TGF- β, CXCR3, RAGE, TNF α, ACC, FAS, SREBP-1c, 
CPT1, LXR α, LXR β, P2X7R, NLRP3, ASC, pro-caspase-1, pro-IL-1β and pro-IL-
18 were quantified  by TaqMan Gene Expression Assays (Applied Biosystems) using 
the primers reported in Table 1. Amplifications were normalized by β-actin and 
quantitation of gene expression was performed using the ΔΔCT calculation, where 
CT is the threshold cycle. The amount of the target gene, normalized to β-actin and 
relative to the calibrator (sample from a WT animal or a nondiabetic individual) was 
given as 2- ΔΔCT. A standard curve for each gene was constructed using multiple 
dilutions of the calibrator. Standard curves were accepted only if the slope was 
approximately -3, with an r value >0.98, and were used to estimate PCR efficiency. 
Results were analyzed using the SDS 2.1 Applied Biosystems software. 
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Table 1. Mouse and human taqman assays 
 
3.8 Statistical analysis 
Results are expressed as means ± SD or median and interquartile range. 
Comparisons between two groups were performed using the Student’s t test or the 
Mann-Whitney U-test for parametric and nonparametric data, respectively. One-way 
ANOVA was used to compare multiple groups, followed by the Student–Newman–
Keuls post hoc test for multiple comparisons. A P value of <0.05 was considered 
statistically significant. 
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Results 
 
 
 
 
 
 
 
 
	   44	  
4.1 Animal kidney studies 
4.1.1 Metabolic parameters. To assess whether P2X7R ablation had any impact 
on the metabolic status of both NFD and HFD-fed mice, thus introducing possible 
confounding effects on the direct role of the P2X7R on HFD-induced renal and liver 
injury, we evaluated the metabolic profile of P2X7R-/- and coeval C57/BL6 WT mice 
fed a HFD or a NFD (Table 1). Body weights, but not kidney weights, were 
significantly higher in mice on a HFD, as compared with animals fed a NFD. 
Likewise, blood glucose and insulin concentrations, the HOMA-IR index, and 
triglyceride and cholesterol levels were higher in HFD- vs. NFD-fed mice, with no 
difference between the two genotypes.  
 
 
 
 
 
 
 
 
 
 
Table 1. Metabolic parameters. Body and kidney weights, blood glucose, serum insulin, 
homeostasis model assessment - insulin resistance (HOMA-IR) index, plasma cholesterol and 
triglycerides in wild type (WT) and P2X7R knockout (P2X7R-/-) mice fed a normal-fat diet (NFD) or a 
high-fat diet (HFD) (mean±SD; n=7 per group). * P<0.001 vs. NFD-fed mice. 
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4.1.2 Renal function and structure. In order to evaluate the impact of P2X7R 
ablation on renal disease, we then assessed the functional and structural alterations 
induced by the HFD in the two genotypes. Serum creatinine levels did not differ 
among the experimental groups, whereas proteinuria and albuminuria increased 
significantly only in the WT animals on a HFD (Table 2). 
 
 
 
 
 
 
 
Table 2. Renal function parameters. Serum creatinine and urinary protein/creatinine (PC) 
and albumin/creatinine (AC) ratio in wild type (WT) and P2X7R knockout (P2X7R-/-) mice fed a 
normal-fat diet (NFD) or a high-fat diet (HFD) (mean±SD; n=7 per group). * P<0.001 vs. NFD-fed 
mice; or † P<0.001 or ‡ P<0.05 vs. WT mice. 
 
 
 
Morphometric analysis of PAS-stained kidney sections revealed that the HFD 
induced glomerular hypertrophy and mesangial expansion in WT mice, as indicated 
by the significant increase of mGA, fMA and mMA, as compared with animals fed a 
NFD. Conversely, P2X7R-/- mice were partially protected from the injurious effects of 
the HFD (Figure 1). 
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Figure 1: Glomerular morphology and morphometry. PAS staining of kidney 
sections from representative WT and P2X7R-/- mice fed a NFD or a HFD (Panel A; original 
magnification 400x); and quantification of mGA (Panel B), fMA (Panel C), and mMA 
(Panel D) in WT and P2X7R-/- mice fed a NFD or a HFD (mean±SD; n=6-7 per group). * 
P<0.001 or † P<0.05 vs. NFD-fed mice; ‡ P<0.001, § P<0.01 or # P<0.05 vs. WT mice. 
PAS = periodic acid Schiff; WT = wild type; P2X7R-/- = knockout for P2X7 receptor; NFD = 
normal fat diet; HFD = high fat diet; mGA = mean glomerular area; fMA = fractional 
mesangial area; mMA = mean mesangial area. 
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4.1.3 Renal/glomerular apoptosis, fibrosis, inflammation and lipid 
accumulation. We then examined the effect of P2X7R deficiency on the fundamental 
processes driving the development of renal disease. Glomerular cell apoptosis 
increased significantly (2.5-fold) only in the WT mice on a HFD (Figure 2, panel A 
and B). Glomerular expression of fibronectin and collagen IV α1 chain were also 
increased in HFD-fed mice, with significantly lower values in P2X7R-/- vs. WT 
animals (Figure 2, panel C,D,E and G). The pro-fibrotic effect of the HFD was 
blunted in P2X7R-/- mice also at the transcriptional level (Figure 2, panel F and H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Glomerular cell and ECM turnover. Immunohistochemistry for active caspase-3 
from representative WT and P2X7R-/- mice fed a HFD (Panel A, arrows =positive cells; original 
magnification 1,000x) and quantification of glomerular cell apoptosis in WT and P2X7R-/- mice fed a 
NFD or a HFD (Panel B); immunohistochemistry for fibronectin (Panel C) and collagen IV α1 chain 
(Panel D) from representative WT and P2X7R-/- mice fed a NFD or a HFD (original magnification 
1,000x), and quantification of fibronectin and collagen IV glomerular protein content (Panels E and 
G) and kidney cortex mRNA expression (Panels F and H) in WT and P2X7R-/- mice fed a NFD or a 
HFD (mean±SD; n=4-6 per group). * P<0.001 vs. NFD-fed mice; † P<0.001 or ‡ P<0.01 vs. WT 
mice. WT = wild type; P2X7R-/- = knockout for P2X7 receptor; HFD = high fat diet; NFD = normal fat 
diet. 
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Furthermore, in response to the HFD, renal cortex protein and mRNA levels of 
the inflammatory markers F4/80 (Figure 3, panel A, C and E) and MCP-1 (Figure 3, 
panel B, D and F) increased markedly in the WT animals, and these changes were 
significantly attenuated in P2X7R-/- mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Renal inflammation. Immunohistochemistry for F4/80 (Panel A; original 
magnification 400x) and MCP-1 (Panel B; original magnification 250x) from representative WT and 
P2X7R-/- mice fed a NFD or a HFD, and quantification of renal cortex protein content of F4/80 (Panel 
C) and MCP-1 (Panel D) and mRNA expression of F4/80 (Panel E) and MCP-1 (Panel F), in WT and 
P2X7R-/- mice fed a NFD or a HFD (mean±SD; n=4-6 per group). * P<0.001 vs. NFD-fed mice; † 
P<0.001 vs. WT mice. MCP-1 = monocyte chemoattractant protein 1; WT = wild type; P2X7R-/- = 
knockout for P2X7 receptor; NFD = normal fat diet; HFD = high fat diet. 
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Finally, ORO staining revealed that the HFD induced marked neutral lipid 
accumulation in the tubular compartment and, to a lesser extent, in the glomeruli, 
with no difference between the two genotypes (figure 4). 
 
 
 
 
 
 
 
 
Figure 4: Renal lipid accumulation. ORO staining (original magnification 400x) from 
representative WT and P2X7R-/- mice fed a HFD. WT = wild type; P2X7R-/- = knockout for P2X7 
receptor; HFD = high fat diet. 
 
 
 
4.1.4 Renal oxidative and carbonyl stress. In view of the recent finding that 
P2X7R is a primary mediator of oxidative stress-induced exacerbation of 
inflammatory tissue injury via NADPH oxidase-dependent mechanisms, as well as of 
the role of ROS as activators of the NLRP3 inflammasome, we also evaluated the 
protein expression level of Nox4, the major NADPHox isoform of the kidney, and 
several markers of tissue oxidative and carbonyl stress. On a HFD, Nox4 was 
markedly up-regulated in WT and to a significantly lower extent in P2X7R-/- mice 
(Figure 5, panel A and B). Similar results were obtained for the activation of NF-
kB/p65 (Figure 5, panel C). Consistently, the glomerular content of CML (Figure 5, 
panel D and E) and HNE adducts (Figure 5, panel F and G) as well as the protein 
expression of RAGE (Figure 5, panel H and I) were higher in mice fed a HFD as 
compared with those on a NFD, again to a significantly lower extent in P2X7R-/- vs. 
WT mice. 
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Figure 5: Renal oxidative and carbonyl stress and NF-kB activation. Immunohistochemistry 
for Nox4 (Panel A), CML (Panel D), HNE adducts (Panel F) and RAGE (Panel H) from 
representative WT and P2X7R-/- mice fed a NFD or a HFD (original magnification 1,000x), and 
quantification of renal cortex protein content of Nox4 (Panel B), CML (Panel E), HNE adducts 
(Panel G) and RAGE (Panel I); activation of NF-κB (Panel C) in WT and P2X7R-/- mice fed a NFD or 
a HFD (mean±SD; n=4-6 per group). * P<0.001 vs. NFD-fed mice; † P<0.01 vs. NFD-fed mice; ‡ 
P<0.001 vs. WT mice. Nox4 = renal isoform 4 of NAD(P)H oxidase; WT = wild type; P2X7R-/- = 
knockout for P2X7 receptor; NFD = normal fat diet; HFD = high fat diet; NFκB = nuclear factor κB; 
CML = Nε-(carboxymethyl)lysine; HNE = 4-hydroxynonenal; RAGE = receptor for AGEs. 
 
4.1.5 Renal expression and activation of the P2X7R/NLRP3 axis. Finally, we 
assessed whether the P2X7R/NLRP3 axis was activated in response to the HFD and 
whether the expression/activation of the NLRP3 inflammasome was affected by 
deletion of the P2X7R gene. P2X7R and NLRP3 expression data are presented in 
Figure 6, whereas the renal expression of NLRP3-associated molecules and 
activation of the NLRP3 inflammasome are shown in Figure 7. Only a very low 
positivity for P2X7R was detected at the tubular level in WT mice fed a NFD. P2X7R 
staining increased in mice on a HFD, both at the tubular level, where the distal 
tubules and macula densa showed the most intense positivity, and at the glomerular 
level, where a positive staining was observed in mesangial cells and especially 
podocytes. (Figure 6, panel A, B and C). Likewise, renal cortex mRNA expression of 
P2X7R were significantly higher in HFD- vs. NFD-fed WT animals, as assessed by 
RT-PCR (Figure 6, panel D).  
Immunohistochemistry revealed mild tubular staining of NLRP3 in both WT and 
P2X7R-/- mice on a NFD. NLRP3 positivity increased significantly in HFD-fed 
animals, showing also glomerular staining, though it was significantly lower in 
P2X7R-/- vs. WT mice (Figure 6, panel E, F and G). Moreover, NLRP3 mRNA levels 
were significantly increased in the renal cortex of WT, but not of P2X7R-/- mice fed a 
HFD (Figure 6, panel H).  
Likewise, the gene expression level of the inflammasome components and 
substrates ASC, pro-caspase-1, pro-IL-1β and pro-IL-18 increased significantly only 
in HFD-fed WT mice (Figure 7, panel A, B, C and D). Western blot analysis of 
caspase-1 in renal cortex extracts showed that the 45 kD subunit (pro-caspase-1) 
increased significantly in response to the HFD in WT, but not in P2X7R-/- mice, 
whereas the 20 kD subunit (active caspase-1) was detectable only in HFD-fed mice 
and was significantly lower in P2X7R-/- vs. WT animals, as the caspase-1:pro-
caspase-1 ratio (Figure 7, panel E and F). Also renal cortex IL-1β and IL-18 protein 
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levels, as assessed by ELISA, increased significantly in HFD-fed mice and 
increments were significantly lower in P2X7R-/- vs. WT animals (Figure 7, panel G 
and H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Renal/glomerular expression of P2X7R and NLRP3. Immunohistochemistry for 
P2X7R (Panel A; original magnification 400x top, 1,000x bottom) from representative WT mice fed a 
NFD or a HFD and for NLRP3 (Panel E; original magnification 400x) from representative WT and 
P2X7R-/- mice fed a NFD or a HFD (arrows =positive cells) and quantification of renal cortex protein 
content and glomerular cell of P2X7R (Panels B-C) and NLRP3 (Panels F-G) positivity; renal cortex 
mRNA expression of P2X7R (Panel D) and NLRP3 (Panel H) in WT and P2X7R-/- mice fed a NFD or 
a HFD (mean±SD; n=4 per group) * P<0.001, † P<0.01 vs. NFD-fed mice; § P<0.001 vs. WT mice. 
NLRP3 = nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain 
containing 3; WT = wild type; P2X7R-/- = knockout for P2X7 receptor; NFD = normal fat diet; HFD = 
high fat diet. 
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Figure 7: Renal expression of NLRP3-associated molecules and activation of the NLRP3 
inflammasome. Renal cortex mRNA expression of ASC (Panel A), caspase-1 (Panel B), pro-IL-1β 
(Panel C) and pro-IL-18 (Panel D); representative Western blot for pro-caspase-1, caspase-1 and β-
actin renal cortex protein expression (Panel E), and quantification of caspase-1/pro-caspase-1 ratio 
(Panel F); and renal cortex levels of IL-1β (Panel G) and IL-18 (Panel H) in WT and P2X7R-/- mice 
fed a NFD or a HFD (mean±SD; n=4 per group). * P<0.001, † P<0.01 or ‡ P<0.05 vs. NFD; § 
P<0.001 or # P<0.01 vs. WT. NLRP3 = nucleotide-binding oligomerization domain, leucine-rich 
repeat and pyrin domain containing 3; ASC = apoptosis-associated speck-like protein containing a 
caspase recruitment domain; IL = interleukin; WT = wild type; P2X7R-/- = knockout for P2X7 receptor; 
NFD = normal fat diet; HFD = high fat diet. 
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4.2 Human kidney studies  
We finally investigated whether the P2X7R-NLRP3 axis was indeed activated also 
in kidneys from 6 type 2 diabetic subjects, as compared with 3 non-diabetic 
individuals (Figure 8). All diabetic subjects except one showed histological features 
consistent with stage 2 or 3 diabetic nephropathy, i.e. glomerular hypertrophy and 
mild to severe mesangial expansion in more than 25% of total mesangium observed 
throughout the sample. Conversely, only one control subject, who had a history of 
hypertension, showed renal lesions (arteriosclerosis) at histological examination 
(Figure 8, panel A). 
Immunohistochemistry revealed an increased positivity for P2X7R (Figure 8, 
panel A, B and C) and NLRP3 (Figure 8, panel A, D and E) in kidneys from diabetic 
vs. non-diabetic subjects, with a staining pattern resembling that observed in mice. 
The mRNA levels of P2X7R, NLRP3 and ASC were also significantly higher in 
patients with type 2 diabetes (Figure 8, panel F, G and H). Interestingly, the non-
diabetic subject with renal lesions had protein and mRNA expression values similar 
to those of diabetic individuals, whereas the diabetic patient with no lesions showed 
values within the range of controls, consistent with the histological features. 
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Figure 8: Human renal tissue P2X7R/NLRP3 inflammasome system. 
Immunohistochemistry for P2X7R and NLRP3 and PAS staining of representative kidney sections 
from non-diabetic control (Ctrl) and diabetic (Diab) subjects (Panel A, arrows =positive cells; original 
magnification 250x), and quantification of renal cortex and glomerular protein content of P2X7R 
(Panels B-C) and NLRP3 (Panels D-E), and renal mRNA expression of P2X7R (Panel F), NLRP3 
(Panel G) and ASC (Panel H) in non-diabetic control (n=3) and diabetic (n=6) subjects (median and 
interquartile range). * P<0.01 or † P<0.05 vs. Ctrl. P2X7R = P2X7 receptor; NLRP3 = nucleotide-
binding oligomerization domain, leucine-rich repeat and pyrin domain containing 3; ASC = apoptosis-
associated speck-like protein containing a caspase recruitment domain. 
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4.3 Animal liver studies 
4.3.1 Liver function. In order to evaluate the impact of P2X7R ablation on HFD-
induced liver disease, we first assessed the functional alterations induced by the HFD 
in the two genotypes. The cytolytic markers aspartate transaminase (AST) and 
alanine transaminase (ALT) increased in the animals mice fed the HFD of both 
genotypes, although the P2X7R-/- mice showed significantly lower values as 
compared with WT, indicating reduced liver damage (Table 3). 
 
 
 
 
Table 3. AST and ALT parameters. AST and ALT in NFD- and HFD-fed WT and P2X7R-/-- 
mice (mean ± SD; n = 7 per group). *P<0.001 vs. NFD; †P<0.001 vs. WT. 
 
4.3.2 Steatosis grading. By the examination of hematoxylin and eosin-stained 
sections, steatosis was detected only in HFD-fed mice, but it was of higher grade in 
WT than in P2x7R-/- mice. In detail, WT HFD mice were ranked in all three grades 
showing predominant grade 3 steatosis. Conversely, P2X7R-/- HFD mice were 
partially protected from the accumulation of lipids, with 4 on 7 mice showing grade 1 
steatosis (Figure 9, panel A and C). 
4.3.3 NAFLD classification P2x7R-/- mice were protected from NAFLD. In fact, 
while 4 on 7 (57%) WT-HFD mice showed stage 3 (mixed steatosis with lobular 
inflammation and ballooning degeneration) and 4 NAFLD (mixed steatosis with 
lobular inflammation and ballooning degeneration and macrovesicular steatosis, 
associated with portal and lobular inflammation, Councilman’s bodies, ballooning 
degeneration, Mallory’s hyaline, and fibrosis), only 1 on 7 (14%) P2x7R-/- animal fell 
into stage 3. The remaining 6 P2X7R-/- mice did not fulfill NASH criteria, with 1 
animal showing stage 2 (predominantly microvesicular steatosis with mild lobular 
inflammation) and 5 animals showing stage 1 (simple steatosis) NAFLD (Figure 9, 
panel A, B and D). 
 
 
	   57	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Steatosis grading, NAFLD classification and NASH grading. Liver sections from 
representative HFD-fed WT and P2X7R-/- mice stained with hematoxylin and eosin (Panel A; original 
magnification 100x, Panel B, 250x) and steatosis grading (Panel C), NAFLD classification (Panel D) 
and NASH grading (Panel E) in NFD- and HFD-fed WT and P2X7R-/- mice (mean ± SD; n = 7 per 
group except E, HFD-fed WT- n=4 and P2X7R-/- n=1 mice fulfilling NASH criteria). p = portal area; 
CV = centrolobular vein; B = ballooning degeneration; M = Mallory’s body; INF = inflammation. * p 
<0.001 vs. NFD-fed mice; † p <0.05 vs. WT mice. WT = wild type; P2X7R-/- = knockout for P2X7 
receptor; NFD = normal fat diet; HFD = high fat diet. 
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4.3.4 NASH grading and staging Of the 4 WT-HFD animals classified as having 
NASH, 3 showed grade 2 (moderate) and 1 grade 3 (severe or florid) NASH, 
whereas 1 exhibited stage 2 (zone 3 portal/periportal, perivenular/centrolobular, 
perisinusoidal/pericellular fibrosis; focal or extensive) and 3 stage 1 (i.e. as stage 2, 
except portal fibrosis) fibrosis, as assessed by the analysis of Masson's trichrome 
stained sections. The sole P2X7R-/- mice fulfilling NASH criteria was graded 1 (mild) 
for NASH and staged 1 for fibrosis. (Figure 9, panel E; Figure 10, panel A and B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. NASH staging. Liver sections from representative HFD-fed WT and P2X7R-/- mice 
stained with Masson’s trichrome (Panel A; original magnification 250x) and NASH staging (Panel B) 
in HFD-fed WT (n= 4) and P2X7R-/- (n= 1) mice fulfilling NASH criteria. The blue color represents 
collagen. WT-HFD mice show perisinusoidal/pericellular and perivenular/centrolobular fibrosis. In 
contrast, P2X7R-/- -HFD mice show no, or very mild, blue staining, indicating a preserved stromal 
architecture of the liver. mean ± SD. CV = centrolobular vein. † p <0.05 vs. WT mice. WT = wild 
type; P2X7R-/- = knockout for P2X7 receptor; HFD = high fat diet. 
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4.3.5 Liver inflammation, fibrosis and lipid metabolism. We then examined the 
effect of P2X7R deficiency on the fundamental processes driving the development of 
liver disease, such as inflammation, fibrosis and lipid metabolism. Transcriptional 
expression of liver inflammatory markers MCP-1, TNF-α and CXCR3 were 
increased in HFD-fed mice, with significantly lower values in P2X7R-/- vs. WT 
animals (Table 4, A). Furthermore, in response to the HFD, mRNA levels of the 
collagen I, fibronectin and TGF-β increased markedly in the WT animals, and these 
changes were significantly attenuated in P2X7R-/- mice (Table 4, B). Finally, 
transcriptional levels of genes implicated in the lipid metabolism of the liver, 
particularly in the lipogenesis, were assessed. Transcriptional expression of liver 
fatty acid synthase (FAS) and liver x receptor (LXR)-α, a transcription factor 
involved in the regulation of cholesterol and fatty acid homeostasis, resulted 
significantly increased only in WT HFD mice; while mRNA levels of Sterol 
Regulatory Element-Binding Proteins (SREBP-1c) and Carnitine 
palmitoyltransferase I (CPT-1) were increased in both genotype fed the HFD, 
resulting however significantly lower in P2X7R-/- mice. Conversely, Acetyl-CoA 
carboxylase (ACC) and LXR-β were not increased by the HFD (Table 4, C).  
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Table 4. Liver inflammation, fibrosis and lipid metabolism. Liver gene expression of 
inflammatory markers (panel A), fibrosis markers (panel B) and lipid metabolism genes (panel C) in 
NFD- and HFD-fed WT and P2X7R-/- mice (mean ± SD; n =7 per group). *P<0.01 vs. NFD; †P<0.05 
vs. WT 
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4.3.6 Liver expression of the P2X7R/NLRP3 axis. Finally, we assessed whether 
the mRNA and protein levels of P2X7R and NLRP3 were modulated in response to 
the HFD and whether P2X7R gene ablation was able to influence the NLRP3 
response to the HFD. When fed the HFD, WT mice showed increased P2X7R IHC 
staining both at the hepatocyte and sinusoidal level (Figure 11, panel A and B). 
Likewise, liver mRNA expression of P2X7R was significantly higher in HFD- vs. 
NFD-fed WT animals, as assessed by RT-PCR ( Figure 11, panel C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Liver expression of P2X7 receptor . Representative immunohistochemistry  of 
liver P2X7R (Panel A; original magnification 100x) in NFD-fed and HFD-fed WT mice, relative 
quantification (Panel B) by image analysis and renal cortex mRNA expression of P2X7R (Panel C) in 
WT mice fed a NFD or a HFD (mean±SD; n=4 per group). Only WT-HFD mice show intense P2X7R 
positivity (brown staining) of liver parenchymal (hepatocytes , astrisk) and non-parenchymal cells 
(sinusoidal lining cells, arrows), mainly around the portal tracts (P). WT = wild type; NFD = normal 
fat diet; HFD = high fat diet. *P<0.001 vs. NFD 
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Also NLRP3 protein level was increased in the liver of WT mice fed the HFD, as 
demonstrated by the de novo appearance of a strong positive staining for NLRP3 in 
cells lining the hepatic sinusoids, bile duct epithelial cells and infiltrating 
inflammatory cells. Interestingly, the NLRP3 staining of these tissue structures was 
virtually absent in P2X7R-/- HFD animals (Figure 12, panel A). Consistently, NLRP3 
mRNA levels were significantly increased in liver of WT, but not of P2X7R-/- mice 
fed a HFD ( Figure 12, panel B) 
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Figure 12. Liver expression of NLRP3 Representative immunohistochemistry of liver 
NLRP3 (Panel A; original magnification 400x top, 1,000x bottom) and renal cortex mRNA expression 
of NLRP3 (Panel B) in WT and P2X7R-/- mice fed a NFD or a HFD (mean±SD; n=4 per group). While 
both WT and P2X7R-/- mice on NFD show no staining for NLRP3, WT-HFD mice display intense 
NLRP3 inflammasome positivity (brown staining) of both resident and non-resident cells. In 
particular, inflammatory cells around degenerating hepatocytes (asterisk), sinusoidal (arrows) and bile 
duct epithelial cells (arrowheads) appear to highly express NLRP3. In contrast, only some isolated 
cells show faint staining for NLRP3 in P2X7R-/--HFD mice. *P<0.001 vs. NFD; †P<0.001 vs. WT. 
NLRP3 = nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain 
containing 3; WT = wild type; P2X7R-/- = knockout for P2X7 receptor; NFD = normal fat diet; HFD = 
high fat diet. 
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Discussion 
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The P2X7 receptor is a purinergic receptor whose pro-inflammatory role is well 
established. Upon activation by its ligand ATP, several downstream events follow, 
including secretion of pro-inflammatory interleukins and apoptosis of the cell (Wiley 
et al. 2011). To date, all the studies conducted on P2X7R-/- mice have associated 
P2X7R to tissue damage induced by immune-mediated diseases, both infectious and 
autoimmune diseases, such as antibody-mediated glomerulonephritis (GN) (Taylor et 
al. 2009), and auto-immune hepatitis (Kawamura et al. 2006), or models of acute 
injury such as the unilateral ureteral obstruction mice model (UUO) (Gonçalves et al. 
2006). To our knowledge, this study provides the first evidence that P2X7R plays a 
major pathogenetic role in the onset and progression of renal and liver disease 
induced by HFD, a mouse model of metabolic disorders characterized by a low-grade 
chronic inflammation.  
Both WT and P2X7R-/- mice fed HFD developed features characteristic of the MS, 
including dyslipidemia, hyperglycemia and insulin resistance. Importantly, these 
metabolic parameters were modified to a similar extent in WT and P2X7R-/- mice on 
a HFD, thus ruling out the possibility that protection from renal and liver injury in 
P2X7R-deficient animals was due to a better metabolic profile.  
 
5.1 Kidney disease. As shown by previous studies conducted on experimental 
animal models, a high saturated fat and/or cholesterol intake induces 
glomerulosclerosis and tubulo-interstitial damage (Deji et al. 2009, Iacobini et al. 
2009, Kume et al. 2007, Jiang et al. 2005). Furthermore, low-grade chronic 
inflammation is known to play a pivotal role in central obesity and the MS 
(Hotamisligil 2006) as well as in the complications of these disorders, including renal 
disease (Krane and Wanner 2011). However, to date, the molecular basis of 
activation of renal pro-inflammatory and fibrogenic signaling pathways by an 
obesogenic high-fat diet is still poorly defined. In this work, we provide evidence 
that P2X7R plays a key role in the pro-inflammatory response, and consequent 
kidney injury, to an high fat intake. In fact, P2X7R-/- mice fed HFD were partially 
protected by both functional and structural renal alterations, showing reduced 
proteinuria and albuminuria, glomerular hypertrophy and mesangial expansion and 
decreased glomerular apoptosis and ECM deposition. This improvement in renal 
structural and functional parameters was associated with  reduced renal tissue 
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inflammation, as shown by lower renal cortex levels of the macrophage marker 
F4/80 and the chemokine MCP-1. Interestingly, P2X7R deletion also resulted in a 
blunted up-regulation of the renal NOX4 by the HFD, which is consistent with the 
reduced oxidative and carbonyl stress and decreased NF-kB activation observed in 
P2X7R-/- mice. 
 
In the normal kidney, P2X7R is expressed at very low levels by both glomerular 
and tubular cells (Gonçalves et al. 2006, Solini et al. 2005, Vonend et al. 2004). 
However, our data clearly show that the HFD induce an up-regulation of this 
purinoreceptor in the renal cortex, glomerulus included, that was associated to signs 
of glomerular injury, such as glomerular hypertrophy, mesangial expansion and 
increased apoptosis. This finding is in keeping with the observation that 
streptozotocin-induced diabetic rats and mice of the Ren-2 renin hypertensive strain 
displayed increased glomerular immunoreactivity for P2X7R (Vonend et al. 2004) 
and that both glucose and free fatty acids (FFAs) rapidly up-regulate P2X7R in 
human islets (Glass et al. 2009). However, a role for P2X7R in chronic kidney 
disease (CKD) was demonstrated only in the UUO model of renal injury by 
Goncalves et al. (2006) that, at variance with our model, is characterized by tubulo-
interstitial damage of mechanical nature. In fact, they showed that P2X7R is 
implicated in macrophage infiltration, collagen deposition and apoptotis in response 
to ureteral obstruction, and that its ablation protect mice from UUO-induced renal 
injury. Finally, our data are in keeping with previous findings showing that P2X7R 
promotes mesangial cell apoptosis (Harada et al. 2000) and favors glucose-induced 
ECM synthesis (Solini et al. 2005). 
Therefore, taken together, our data provide for the first time in vivo evidence for 
the involvement of the P2X7R in the onset and progression of CKD associated to 
metabolic disorders and support a role for dyslipidemia in P2X7R modulation. 
 
5.1.1 P2X7R and NLRP3 inflammasome. Recent evidence suggests that the 
inflammasomes, particularly the NLRP3 inflammasome, are implicated in chronic 
low-grade sterile inflammation characterizing disorders like the MS (Strowig et al. 
2012, Wen et al. 2012). In dietary and genetic animal models of obesity and the MS, 
activation of the NLRP3 inflammasome has been shown to participate in the 
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induction of obesity by impairing adipocyte differentiation and increasing adipocyte 
size (Stienstra et al. 2011, Stienstra et al. 2010) as well as in the instigation of 
inflammation in adipose tissue and liver (Vandanmagsar et al. 2011), thus favoring 
insulin resistance. However, it is still unknown which mechanisms are involved in 
NLRP3 activation. Our results show that NLRP3 and the inflammasome components 
ASC and caspase-1 were up-regulated in the kidney of WT mice fed with the HFD 
and that P2X7R ablation totally prevented this effect. Moreover, they provide the first 
evidence that P2X7R acts as an NLRP3 inflammasome activator in HFD-induced 
renal inflammation and injury, as evidenced by a significantly lower level of the 
mature forms of both caspase-1 and IL1β and 18 in P2X7R-/- mice vs. WT. This is 
consistent with separate observations showing that ablation of either P2X7R 
(Gonçalves et al. 2006) or NLRP3 (Vilaysane et al. 2010) attenuate macrophage 
infiltration, collagen deposition and apoptosis in UUO.  
The relationship  between NLRP3 activation and P2X7R signaling points to a 
major role of the purinergic system in regulating the activity of the NLRP3 
inflammasome in the kidney in response to a HFD, at variance with obesity-
associated inflammasome activation in adipose tissue, which was shown to be 
unaffected by P2X7R ablation (Sun et al. 2012). This latter finding is consistent with 
our results that metabolic parameters were worsened to a similar extent in WT and 
P2X7R-/- mice on a HFD. This is also in keeping with the concept that regulation of 
inflammasome activation is tissue-specific. On the other side, the observation that 
post-translational processing of pro-caspase-1, a marker of inflammasome activation 
(Yazdi et al. 2010), as well as renal inflammation and injury were not completely 
suppressed in P2X7R-/- mice suggests that other inflammasomes and/or non-
inflammasome pro-inflammatory pathways participate in HFD-induced renal disease. 
Three, not mutually exclusive models have been proposed for inflammasome 
activation (Schroder and Tschopp 2010): pore formation, induced by eATP via 
P2X7R or by pore-forming toxins, which triggers K+ efflux and allows extracellular 
NLRP3 agonists to access the cytosol; frustrated phagocytosis of crystalline and 
particulate structures, with consequent lysosomal disintegration and release of 
proteases; and ROS generation via NADPH oxidase or mitochondrial sources, which 
may represent a common final pathway. All three models might be involved in the 
activation of the NLRP3 inflammasome in HFD-fed mice, via multiple signals 
including saturated FFAs such as palmitate (Wen et al. 2011), the product of long 
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chain saturated FFAs ceramide (Vandanmagsar et al. 2011), modified lipoproteins 
such as oxidized LDLs, via formation of cholesterol crystals (Duewell et al. 2010), 
glucose, ROS, and eATP and uric acid released by dead cells (Strowig et al. 2012). 
The finding that activation of the NLRP3 inflammasome was blunted by P2X7R 
ablation implies that P2X7R plays a central role in this phenomenon and suggests that 
FFAs and glucose, by up-regulating P2X7R (Glas et al. 2009), as well as eATP, by 
engaging P2X7R (Ward et al. 2010), are likely involved in NLRP3 activation under 
these conditions. 
An important observation of our study is that not only the activation of the 
NLRP3 inflammasome, but also the activation of the NF-kB and, consequently, the 
transcription of the inflammasome components and targets were reduced by P2X7R 
ablation. As known, the generation of mature IL-1β and IL-18 involves two separate 
processes to avoid their inappropriate and deleterious release: the induction of NF-
kB-dependent mRNA expression and translation of the procytokine upon activation 
by most PRRs (signal 1) followed by cleavage of the procytokine and release of its 
mature and active form via NLRP3 inflammasome activation (signal 2). It is 
plausible that the strong reduction of the NF-kB activation in P2X7R-/- mice fed HFD 
vs. WT can result from a damping in P2X7R-deficient mice of the auto-activating 
positive loop, by which mature inflammatory cytokines, including IL1β and IL18, 
binding to their membrane receptor, trigger the NF-kB activation stimulating the 
overexpression of themselves (Bonizzi and Karin 2004). On the other hand, the 
demonstration by Liu and colleagues that P2X7R is involved in the activation of NF-
kB, mediated probably by a direct interaction with LPS and ATP (Liu et al. 2011), in 
addition to the evidence that biglycan, an ECM component released during ECM 
remodeling, was shown to mediate the interaction of TLR2/4 with P2X7R /P2X4R, 
thus leading to both priming and activation of the NLRP3 inflammasome (Babelova 
et al. 2009), suggests that in our model this receptor can play also a direct role in NF-
kB activation, so acting not only as signal 2 but also as signal 1 in the NLRP3 
inflammasome activation. 
Moreover, although no differences in kidney lipid accumulation between the two 
genotype were present, P2X7R-/- mice fed HFD vs. WT showed lower oxidative and 
carbonyl stress. This is consistent with the reduced protein expression of the renal 
isoform of NADPH oxidase, NOX 4, associated with the ablation of P2X7R. These 
data are supported by the recent demonstration that P2X7R is a mediator of oxidative 
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stress via NADPH oxidase both in vivo (Chatterjee et al. 2012) and in vitro (Liu et 
al. 2011, Korcok et al. 2004) and corroborate a role for this receptor as a source of 
ROS signals for priming and possibly activation of the NLRP3 inflammasome. 
 
Finally, data from human kidneys support a role for the P2X7R -NLRP3 axis also 
in renal disease associated with type 2 diabetes and metabolic disorders, consistent 
with a previous report that NLRP3 mRNA expression was increased in human renal 
biopsies from subjects with non-diabetic CKD (Vilaysane et al. 2010). A causal role 
for the NLRP3 inflammasome has been recently suggested by the observations that 
IL-1 receptor antagonist gene polymorphism affects CKD progression, especially in 
subjects with diabetic nephropathy (Buraczynska et al. 2006), and that a human-
engineered monoclonal anti-IL-1β antibody reduces inflammation in patients with 
type 2 diabetes (Cavelti-Weder et al. 2012). 
 
5.2 Liver disease. Non-alcoholic fatty liver disease (NAFLD) is one of the major 
complications of the insulin resistance and MS (Marchesini et al. 2003), that 
encompasses various pathologic conditions, from simple steatosis to nonalcoholic 
steato-hepatitis (NASH), cirrhosis, and possibly hepatocellular carcinoma (Erickson 
2009). Fat accumulates within the liver via increased fatty acid (FA) delivery from 
adipose tissue and diet and enhanced hepatic FA import and synthesis exceeding the 
rate of FA export and catabolism (Bradbury and Berk 2004)  
To date, the involvement of P2X7R in the pathophysiology of liver disease is 
largely unknown and restricted to model of acute hepatic injury induced by toxic 
substances (Hoque et al. 2012, Chatterjee et al. 2012.). Here, we provide the first 
evidence that P2X7R ablation influences the earlier steps of NAFLD, i.e. steatosis, 
hepatocyte injury, and inflammation, since P2X7R-deficient mice showed marked 
attenuation or even prevention of NASH induced by a high fat diet. NASH 
prevention/attenuation was attested by reduced infiltration of inflammatory cells, 
blunted up-regulation of proinflammatory cytokines and transcription factor and 
decreased fibrosis. 
Hepatic fat accumulation was also lower in the liver of P2X7R-/- than in WT mice 
fed the HFD, despite similar increases in circulating lipids and the same extent of 
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insulin resistance (IR). This may be attributed to the improved hepatic lipid 
metabolism showed by the transgenic mice, resulting from the lower transcriptional 
levels of genes implicated in the lipogenesis process and a more favorable 
modulation of genes involved in the regulation of cholesterol and fatty acid 
homeostasis. So, we can speculate that P2X7R ablation protects mice from the onset 
of early pro-inflammatory changes induced by increase of fatty acids delivery from 
adipose tissue and diet, thus limiting hepatocytes injury and, consequently, their lipid 
metabolism impairment. This series of events, in turn, causes a lower fat 
accumulation, i.e. steatosis, and, over time, less inflammation characteristic of 
NASH in P2X7R-/- mice fed HFD vs. WT. 
To date, the mechanism through which the P2X7R exerts its pro-inflammatory role 
in HFD-induced NAFLD is unknown. However, the strong NLRP3 positive staining 
of some liver structures (i.e., hepatic sinusoids, bile duct epithelial cells) and 
infiltrating inflammatory cells observed in WT mice fed HFD, but not in P2X7R-/- 
HFD animals, suggests that in the liver, as well as in the kidney, P2X7R may act as 
an NLRP3 inflammasome modulator/activator. Consistently with this hypothesis, 
Csak and colleagues recently showed an implication of the NLRP3 inflammasome in 
the pathogenesis of NASH induced by methionine choline-deficient (MCD) or long-
term high fat diet, proving that the saturated fatty acid (FA) palmitic acid (PA) 
activates the inflammasome in the liver and induces sensitization to 
lipopolysaccharide (LPS)-induced IL1β release in hepatocytes. Furthermore, 
hepatocytes exposed to saturated FAs release danger signals that trigger 
inflammasome activation in immune cells (Csak et al. 2011). However, more work is 
needed to confirm this speculation.  
 
 
Conclusion. In conclusion, these data demonstrate a major contribution of the 
P2X7R in the process driving both renal and hepatic inflammation and injury 
associated with metabolic disorders. Moreover, at least in the kidney, P2X7R acts as 
both signal 1 and signal 2 in the induction and activation of the NLRP3 
inflammasome. Thus, this study identifies P2X7R and NLRP3 as novel therapeutic 
targets for kidney and liver disease associated with metabolic disorders such as type 
2 diabetes and the metabolic syndrome. 
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